



Ketogenic Dietitians
Research Network



EPILEPSY


CLASSICAL KETOGENIC DIETS FOR CHILDREN AND YOUNG PEOPLE WITH DRUG-RESISTANT EPILEPSY

A reflection of international dietetic practice and
best practice recommendations for dietitians

For Healthcare professionals only.
Not for distribution to general public.



This booklet has been adapted from Schoeler, N.E., Whiteley, V.J. et al, Classical and Modified Ketogenic Diets for Children and Young People With Drug-Resistant Epilepsy: A Reflection of International Dietetic Practice and Best Practice Recommendations for Dietitians. Journal of Human Nutrition and Dietetics, 38: e70129.



To access the publication
scan the QR code.

The original study and production of this booklet was funded by Nutricia.

TABLE OF CONTENTS

ABSTRACT	4
KEY POINTS	4
1. INTRODUCTION	5
2. MATERIALS AND METHODS	6
3. RESULTS: INTERNATIONAL DIETETIC PRACTICE	8
4. RESULTS: DIETETIC PRACTICE CORE RECOMMENDATIONS	28
5. DISCUSSION	31
6. CONCLUSION	32
ABBREVIATIONS	32
REFERENCES	33
SUPPLEMENTARY MATERIAL	38

ABSTRACT

Introduction: A global need was identified for a practical, comprehensive tool to guide dietitians internationally working in ketogenic diet therapy (KDT), detailing all aspects of dietetic management. The aim of this project was to develop best practice recommendations for the dietetic management of classical ketogenic diets in the management of epilepsy and neurometabolic conditions.

Methods: Expert ketogenic dietitians from six continents were invited to participate as members of either a core working group or advisory group. A systematic literature review was conducted, covering all aspects of dietetic management, from patient selection to diet discontinuation. To complement this, an international survey was distributed to ketogenic dietitians currently delivering classical ketogenic diets, structured around the same key themes.

Results: A total of 111 dietitians responded to the survey, representing six continents. For each theme, findings from the literature were presented alongside survey responses. Recommendations were generated where $\geq 75\%$ consensus was achieved. In areas where this threshold was not met, the most commonly reported practices were presented, acknowledging the variety of international approaches.

Conclusion: These are the first international best practice recommendations specifically for ketogenic dietitians and nutrition healthcare professionals supporting children following medically advised classical ketogenic diets. The recommendations are informed by both published evidence and prevailing international dietetic practice, whilst recognizing the variety in clinical delivery.

Keywords: modified ketogenic diet; epilepsy; dietetic; guidelines; clinical.

KEY POINTS

- Classical ketogenic diets are defined as ‘ketogenic diets that are based on a ratio of grams of fat to grams of protein and carbohydrate combined, usually ranging from 2:1 to 4:1’, based on our international survey responses.
- This manuscript outlines the first international best practice recommendations aimed at dietitians managing children and young people with epilepsy referred for treatment with a classical or modified ketogenic diet, as part of a multi-disciplinary team. All aspects of dietetic management are covered, from patient selection to diet discontinuation.

1. INTRODUCTION

Ketogenic diet therapy (KDT) is an umbrella term describing a group of high-fat, low-carbohydrate, moderate protein diets used as a management option for drug-resistant epilepsy.

The classical ketogenic diet (CKD) is the 'original' form of KDT, described by Wilder in 1921¹, and is based on a ratio of grams of fat to grams of carbohydrate and protein combined. We adopt the terminology 'classical', coined in 1989², in keeping with the dictionary term meaning 'traditional in style or form' (Cambridge Dictionary), as used in the UK, mainland Europe and further afield; we do, however, acknowledge that the term 'classic' ketogenic diet is also used, particularly in the USA, as has been debated in recent literature³. To allow for a higher carbohydrate intake and/or protein without compromising ketosis, Huttenlocher later introduced a variant of KDT incorporating medium chain triglyceride (MCT) fat, with 60% of energy derived from MCTs⁴. A modified version using 30% of calories from MCT was subsequently developed to reduce gastrointestinal side effects².

In 2006, following a case series of six individuals with epilepsy treated with a version of the popular 'Atkins' diet⁵, the 'modified Atkins diet' (MAD) was formally described⁶. MAD typically restricts carbohydrate to 10g/day for the first month, encourages high fat intake, and allows unrestricted protein. More recently, the term 'modified ketogenic diet' (MKD) has appeared in the epilepsy literature, although it was not comprehensively described until 2019⁷. Another variation, the low-glycemic index treatment (LGIT), is a more liberal low-carbohydrate diet that may or may not be ketogenic⁸. LGIT typically permits 40-60g of carbohydrate per day, all with a glycemic index <50, with fat comprising 60-70% and protein 20-30% of total energy intake.

Optimal clinical management recommendations for healthcare professionals managing children with epilepsy on KDT were updated in 2018⁹. While these include guidance relevant to dietitians, they are predominantly clinically focused and do not explore the full spectrum of dietetic practice, such as calculating prescriptions or initiating or discontinuing KDT.

A clear gap was identified for a practical resource tailored to the needs of dietitians delivering KDT. We aimed to explore the breadth of international dietetic practice in KDT and develop best practice recommendations informed by the published literature and the most commonly reported approaches in clinical practice.

2. MATERIALS AND METHODS

A call for expert volunteers to contribute to the development of ‘best practice dietetic recommendations for classical ketogenic diets’ was circulated via the Ketogenic Dietitians Research Network (KDRN) and ketogenic dietitians .listserv mailing list.

Sixteen dietitians were selected to form the core working group, each with a minimum of five years’ clinical experience in KDT, including the use of CKD. Where possible, the number of dietitians from each geographical area (USA, Canada, UK and Europe, Central and South America, Middle East and Asia, Africa and Oceania) was aligned proportionally to the number of ketogenic centers in that area, based on listings from The Charlie Foundation, Matthew’s Friends and The International League Against Epilepsy. In the case of over-representation of volunteers from one country/continent, selection was based on a short written statement outlining each candidate’s experience and capacity to contribute to the project. Due to overwhelming interest from certain regions, an additional ‘advisory group’ was formed to provide expert review of draft manuscripts. As with the core group, efforts were made to ensure proportional representation by geographical area, relative to the number of ketogenic centres.

2.1. Literature Search

A dedicated subgroup of the core working group conducted the literature review. A virtual training session was delivered and the topics and search strategy were standardized and agreed.

Each subgroup member was assigned a specific subtopic, with the aim of collating published evidence related to the dietetic management of CKDs, ranging from initial referral to diet discontinuation. The subtopics included:

- Patient selection
- Pre-diet preparation (dietetic and psychosocial)
- Diet prescription, including macronutrients, fluids, vitamins and minerals, enteral feeding, special dietary requirements, different age groups
- Prescribable ketogenic products
- Diet initiation
- Monitoring, including adverse effects, management of illness, psychosocial impact, adherence and tele-healthcare
- Diet discontinuation

The following core terms were used to search the online PubMed database, last updated on 24/02/2024: (child* OR infant) AND (ketogenic OR “modified atkins”) AND (epilepsy OR seizure*), followed by additional search terms according to the subtopic (see Table S1 for full search terms). Relevant data were extracted into a structured Excel template capturing the following fields: author, year of publication, article title, study design, age of participants/cohort, type of KDT and details relevant to each subtopic. Findings for each subtopic were then summarised in bullet-point format.

Of 530 articles retrieved from the literature search, 155 studies were included following title/abstract and full-text screening. Of the 155, five articles addressed patient selection, 20 pre-diet preparation, 23 diet prescription, 11 prescribable ketogenic products, 39 diet initiation, 50 diet monitoring and 12 addressed diet discontinuation.

2.2. Survey

A subgroup of the core working group was responsible for developing and delivering the survey. A total of 131 multiple choice questions were created, aligned with the same subtopics explored in the literature review. Each question included a free-text or 'other' option to allow respondents to describe alternative practices and capture the diversity of global dietetic approaches. The survey was distributed via KDRN and .listserv using the online platform SmartSurvey™ (SmartSurvey Ltd, Tewkesbury, United Kingdom).

A total of 111 dietitians anonymously completed the survey, with the following proportion geographical representation: Europe (31%), North America (23%), South America (14%), Australia (11%), Southeast Asia (6%), East Asia (5%), Canada (4%), New Zealand (4%), Southern Africa (3%), South Asia (1%) and West Asia (1%).

Survey responses were summarized using descriptive statistics. For questions where participants could 'Select all that apply,' response percentages may exceed 100%. Where questions required a choice between types of KDT (e.g. for specific patient populations), only CKD and MKDs were presented as options, reflecting the specific focus of this project (see separate resource for MKD recommendations). All survey answers are available upon request from the authors.

2.3. Writing the 'Best practice recommendations'

Bullet-point summaries from the literature review formed the basis of the main document and were presented alongside the corresponding survey results. To reflect the diversity of international dietetic practice while maintaining clarity and conciseness, survey answers selected by ≥5% of respondents were included. In specific cases, such as reporting on the length of time taken to discontinue KDT, all response options were presented in full. Unless otherwise stated, all percentages reported in the text refer to the proportion of respondents selecting that particular answer in the survey. A set of core recommendations was developed for each aspect of CKD dietary management.

These were drawn from either:

- published literature (restricted to published consensus recommendations, international guidelines, systematic reviews, meta-analyses or randomized controlled trials), or
- survey responses that reached a consensus threshold of ≥75%. Where this threshold was not achieved in survey responses (for example, with 'Select all that apply' questions), the most commonly selected option(s) were reported and wording carefully chosen to acknowledge the variability in dietetic practice.

The worked examples and meal planning sections were developed based on the clinical experience of the core and advisory working groups to give practical suggestions to readers. The draft manuscript and recommendations were first reviewed by the core working group. Following revisions, the updated manuscript was reviewed by the advisory group. Any points of contention were discussed and resolved via virtual meeting.

3. RESULTS: INTERNATIONAL DIETETIC PRACTICE

3.1. Defining classical ketogenic diets

The CKD is the original form of KDT, first described by Wilder in 1921¹. It remains the most commonly used KDT in clinical practice¹⁰. The diet protocol is based on a ratio of grams of fat, to grams of protein and carbohydrate, with each meal or feed carefully calculated. While the literature suggests that ratios above 1.7:1 promote ketogenesis¹¹, in practice, lower ratios may still be effective depending on the individual's metabolic response. In the survey, 77% of survey respondents defined CKDs as those with a fat to non-fat ratio between 2:1 to 4:1. A further 18% considered only higher ratios (3:1 to 4:1) to qualify as a CKD. Additionally, 27% defined CKDs as dietary protocols that require all foods to be weighed on a gram scale.

Based on the most common survey responses, this guideline defines CKDs as 'ketogenic diets that are based on a ratio of grams of fat to grams of protein and carbohydrate combined, usually ranging from 2:1 to 4:1'.

3.2. Patient selection

The role of the multidisciplinary team (MDT) is paramount in deciding whether to accept an individual to start KDT. Ideally, all potential patients should be evaluated within a tertiary epilepsy specialist center, where medical, dietetic, and psychosocial factors can be jointly considered¹². Typically, the medical team leads on referral and/or acceptance of patients for consideration of KDT.

All patients referred for KDT should be screened for metabolic contraindications prior to initiation. This includes testing serum acylcarnitine profile and/or urine organic acids or serum amino acids⁹. There is currently no definitive consensus regarding the use of KDT during pregnancy¹³. Adolescent females of child-bearing age should be advised to exercise caution and, where pregnancy is confirmed or planned, the decision to initiate or continue KDT should be based on a careful risk-benefit assessment. From a dietetic perspective, certain factors that may complicate following KDT should also be screened for and considered prior to accepting a referral (Table 1).

Table 1. Potential contraindications to ketogenic diet therapy: survey responses

Factor	Agreement rate (% survey respondents)
Medication/treatment non-compliance	63%
Lack of family support	61%
Long-term parenteral nutrition	52%
Difficulties with reading and/or understanding (patient or family, as appropriate)	51%
Severe picky eating	50%
Emesis	47%
Gastrointestinal disorders (gastroparesis, short bowel etc)	46%
Poor oral intake, especially fluids and/or formula	38%
Bone fragility	28%
Financial difficulties	26%
Gastro-esophageal reflux	23%
Endocrine disorders	22%
Language difficulties (e.g. if their native language is different to that of the clinical team)	21%
History of aspiration pneumonia	16%

Note: none of the above are necessarily absolute contraindications to starting a medical ketogenic diet, but rather factors to consider. The risk-benefit ratio should be considered in each individual.

3.2.1. Survey results

Table 1 outlines factors that, according to survey respondents, may complicate following KDT.

CKD was favoured over MKDs by respondents in the following scenarios:

- Enteral feeding (88%)
- Age < 2 years (70%)
- Clinically unstable, hence needing to get better seizure control quickly (66%)
- Family preference (58%)
- Epilepsy syndrome/type, e.g. Glucose Transporter Type 1 Deficiency Syndrome (GLUT1DS) (41%) or Pyruvate Dehydrogenase Deficiency (PDHD) (42%)

For individuals with GLUT1DS, 35% of survey respondents preferred either CKD or MKDs, depending on contextual factors such as patient age, family understanding, age at diagnosis, age at diet start, mode of feeding, symptom severity, anticipated diet duration, and patient acceptance of dietary change. CKD was preferred in infants under 1 year of age. For individuals with PDHD, 42% of survey respondents preferred CKD, while 31% reported that either CKD or MKDs could be appropriate depending on individual circumstance.

3.3. Pre-diet preparation

In addition to medical team responsibilities, such as baseline laboratory assessments, nutrition/dietetic and psychosocial preparation play a crucial role in setting the foundation for successful KDT.

3.3.1. Dietetic assessment and preparation

As part of the pre-diet preparation, the dietitian should complete a comprehensive diet history. This may include a 3-day dietary record and/or a detailed account of their usual dietary intake, including feeding method, textures tolerated, food allergies, intolerances and other special dietary requirements. Conducting a diet history not only helps to establish the patient and families commitment to KDT, but also provides invaluable insight into habitual calorie intake, eating behaviours, and personal or cultural preferences¹⁴.

Any food allergies, intolerances or special dietary requirements should be carefully documented and considered within the KDT prescription. A thorough review of current and previously trialled formulas or foods can help avoid unnecessary dietary restrictions¹⁵.

The dietitian should also collect baseline anthropometry measurements, including weight and length/height, and where appropriate, mid-upper arm circumference and skinfold thickness. These measurements, along with growth history and laboratory results, such as full blood count, ferritin and vitamin D levels, support the assessment of the patient's nutritional status and requirements to inform the diet prescription¹⁴. It is also important to determine whether the patient is already or has previously been, under dietetic care.

Survey findings showed that over half of survey respondents recommend that patients make dietary adjustments prior to KDT initiation, for example by reducing simple sugars (59%), trying out high-fat foods (49%) or trying keto foods/recipes (46%).

3.3.2. Patient / family education and counselling

Parental education is a critical component of KDT and plays a major role in both diet initiation and long-term adherence. While clinical and nutritional safety form the foundation of the education, discussions should also address the broader implications of following a restrictive medical diet. These conversations help minimize potential financial, developmental and psychological burdens, and can improve family preparedness and reduce the risk of non-adherence¹⁶⁻¹⁹.

The literature identifies key barriers to KDT adherence, which should be explored during education sessions:

- Time investment required for meal/feed preparation^{16,19}
- Adverse effects of KDT¹⁶
- Parental anxiety pre-diet²⁰
- The cost of KDT-compatible supplements and/or specific foods²¹
- Cultural adaptability of KDT²⁰
- Disruption of the home environment²⁰
- Poor palatability and restrictiveness of KDT¹⁶.

To support families effectively, clinicians should assess the family's capabilities (knowledge, skills and ability to make dietary change), their resources (food availability, support from school, etc), and their motivation to start KDT in order to best support adherence. Some centres may be equipped with a social worker or child life specialist who can assist but, often, the dietitian plays a central role in this process. Dietitians must also be aware of the patient/family's culture and religious, and socioeconomic background to ensure that education is delivered sensitively and appropriately^{16,17,21}.

3.3.2.1. Survey results

Survey findings revealed that 92% of respondents delivered at least one structured education session before starting KDT. Education is provided individually (77%) or via group sessions (5%); the timing of the education varies either before (31%), as part of (23%) or after (28%) the baseline visit.

Education sessions are most often led by the dietitian, but may also involve other members of the multidisciplinary team, including specialist nurses, medical doctors, dietetic assistants/support workers or clinical psychologists. The format of education varies across centres, with sessions delivered face-to-face, virtually, or by telephone, depending on local service models and family preference.

A wide range of topics are covered in these sessions, tailored to the individual patient and family. The most commonly covered topics, according to survey responses, are outlined in Table 2.

Table 2. Topics to cover in initial education sessions for patients/families: survey responses

Topic	Agreement rate (% survey respondents)
Importance of adherence to the diet	94%
Potential adverse effects	93%
Follow-up expectations	86%
Identifying carbohydrates, protein and fat sources	83%
Weighing/measuring of foods and/or formula	83%
Importance of hydration	81%
Other sources of carbohydrates, such as medications	80%
Supplementation	79%
Time commitment needed for ketogenic diets	77%
How to check ketone levels	69%
How to recognize symptoms of hyperketosis and hypoglycemia	68%
Potential impact on quality of life (may be negative or positive)	64%
Other non-food sources of carbohydrates	60%
Potential social/personal impact of following a restricted diet when around others	59%
How to use a ketone/blood glucose monitor	59%
Developing recipes and using meal calculation tools	56%
Insurance coverage and/or availability of supplies required for monitoring and diet	55%
Plan for sick days	51%
The cost of ketogenic diet-suitable foods	42%
Strategies to manage special occasions	41%
Physical activity with reference to bone health	10%

3.4. Diet prescription

Literature review data are outlined in the below sections, according to specific macronutrients.

88% of survey respondents indicated that the dietitian is responsible for calculating the initial diet prescription. The most commonly reported factors influencing macronutrient targets were:

- Age (64%)
- Usual diet (44%)
- Epilepsy syndrome (36%)
- Medications (14%)
- Physical activity levels (13%)
- Calorie and protein requirements (6%).

An example calculation for CKD is presented in Figure 1, based on the most commonly used macronutrient targets and prescription strategies reported in the survey. Calculations are presented using the dietary unit method, as described by Kossoff²². In this approach, a dietary unit represents the combined caloric contribution of fat, protein, and carbohydrate based on a specific fat-to-non-fat ratio. For example, in a 4:1 ratio, a dietary unit is calculated as $(4 \times 9 \text{ kcal}) + (1 \times 4 \text{ kcal}) = 40 \text{ kcal}$ per unit. This unit-based approach allows for structured meal planning while maintaining the prescribed ketogenic ratio.

Figure 1. An example calculation for CKD

Step 1	Calculate calorie and protein requirements.
Step 2	To calculate the dietary units allowed daily, divide the number of daily calories required by the number of calories in the dietary unit (e.g. 40 kcal for 4:1 ratio).
Step 3	To calculate the total daily allowance of fat in grams, multiply the number of units allowed daily by the units of fat in the ratio (e.g. 4 for a 4:1 ratio).
Step 4	The number of units allowed daily for protein and carbohydrate combined is 1 (e.g. for a 4:1 ratio). To calculate the total daily allowance of carbohydrate in grams, subtract the grams of protein from the total number of dietary units allowed daily.
Step 5	You now have your daily allowance of fat, protein and carbohydrate. These can be divided equally into the number of meals/feeds and/or snacks, as required.

Example 1

Patient details: 9-year-old child 'Jamie'

A food diary estimates his

Intake: 1340 kcal/day

Weight: 20 kg

Meal pattern: 3 main meals

and 2 snacks each day

Target: 3:1 CKD ratio

Example 2

Patient details: 15-month-old child 'Alex'

A food diary estimates his

Intake: 650 kcal/day

Weight: 9 kg

Meal pattern: He has 3 meals,

1 snack and a supper each day

Target: 2:1 CKD ratio

Estimated daily requirements	- Calories = 1340 kcal - Protein = 20 g/day (1 g/kg/day)	- Calories = 650 kcal - Protein = 10.3 g/day (1.14 g/kg/day = 10.3 g)
Kcal/Dietary unit	$(9 \text{ kcal} \times 3) + (4 \text{ kcal} \times 1) = 31 \text{ kcal per dietary unit}$	$(9 \text{ kcal} \times 2) + (4 \text{ kcal} \times 1) = 22 \text{ kcal per dietary unit}$
Calculation of daily dietary units	$1340 \div 31 = 43.2 \text{ units daily}$	$646 \div 22 = 29.4 \text{ units daily}$
Fat = number of units x ratio	$43.2 \times 3 = 129.6 \text{ g}$	$29.4 \times 2 = 58.8 \text{ g}$
Protein and carbohydrate = number of units x ratio	$43.2 \times 1 = 43.2 \text{ g}$	$29.4 \times 1 = 29.4 \text{ g}$
Protein = RNI/DRI (or minimum 1 g/kg)	20 g	10.3 g
Carbohydrate = number of units minus grams of protein	$43.2 - 20 \text{ g} = 23.2 \text{ g}$	$29.4 - 10.3 = 19.1 \text{ g}$
Nutrition prescription <i>*Values rounded to whole numbers for ease of meal calculations</i>	130 g fat 20 g protein 23 g Carbohydrate	60 g fat 10 g protein 19 g Carbohydrate
Dietary plan	3 main meals = 32 g fat, 5 g protein and 5 g carbohydrate 2 snacks = 17g fat, 2 g protein and 4 g carbohydrate	5 meals/snacks = 12 g fat, 2 g protein and 4 g Carbohydrate

3.4.1. Energy

Historically, CKDs were prescribed with caloric restriction (80-90% of estimated requirements) in an attempt to promote ketosis and seizure control. However, evidence suggests that energy restriction does not provide additional benefit, and may even hinder growth, particularly in younger patients or those with already compromised nutritional status. As a result, caloric restriction is no longer routinely recommended⁹.

Accurate estimation of energy requirements is important when setting specific macronutrient targets, especially for CKD. Energy requirements may be estimated using age and gender-specific equations for Estimated Average Requirements (either country-specific or from the World Health Organization²³). For children with neurological disabilities, standard equations may not reflect true energy needs, which can be influenced by mobility, feeding difficulties, altered metabolism, and disease severity. A detailed food diary, and growth history, should be used alongside predictive equations to guide appropriate energy prescriptions.

The following percentage of survey respondents adopt the following practices for CKD prescriptions (multiple responses could be selected):

- 86% consider the patient's current energy intake
- 82% use standardised energy equations
- 71% factor in recent growth trends
- 12% still apply slight energy restriction, typically targeting 90% of estimated needs, to account for lower respiratory quotient or reduced activity levels

3.4.2. Choice of ratio

The choice of initial target ratio varies depending on factors such as age, clinical setting (e.g. critical care or outpatients) or clinical need (e.g. higher ratios may be desired sooner for optimal ketosis and clinical improvements). In practice, 35% of survey respondents start at a lower ratio and increase the ratio over time, with the aim of increasing ketosis and/or clinical efficacy. In contrast, 20% favor starting CKD at a higher ratio and then reduce the ratio over time, depending on ketone levels, clinical efficacy, or adverse effects. All meals and snacks are usually in the same diet ratio, so the relative proportions of macronutrients remain the same throughout the day.

3.4.3. Fat

With CKDs, the prescribed ketogenic ratio determines the quantity in the diet. A higher ratio corresponds to a greater proportion of energy from fat. For example, in a 4:1 CKD, there are 4 grams of fat for every 1 gram of protein and carbohydrate combined, meaning that approximately 90% of the daily energy is derived from fat. Fat in CKDs is typically sourced from long-chain triglyceride (LCT) sources, although MCTs may be included to enhance ketone production and allow for a slightly more liberal intake of carbohydrate or protein.

3.4.4. Protein

In the CKD literature, protein intake is typically prescribed in grams/kg body weight, using Dietary Reference Intakes (DRI) or Reference Nutrient Intake (RNI) for age²⁴. Individualised dietetic judgement is essential, with regular reassessment of nutritional adequacy through growth monitoring, clinical review, and biochemical parameters. While protein must be carefully calculated to maintain the ketogenic ratio, it should still meet the child's physiological requirements. Some protocols aim to meet the lowest safe level of protein intake to preserve the ketogenic ratio, whereas others prioritise ensuring at least the minimum recommended daily intake. In practice, a balance is often sought between maintaining ketosis and supporting adequate growth and nutritional status.

Survey respondents demonstrated a range of approaches to protein prescription. In the context of CKD, nearly half of practitioners (46%) reported that they provide protein to meet the DRI or RNI as a minimum, while 54% aim to meet the full DRI. Just over half of respondents (53%) indicated that they prioritise protein over carbohydrate when calculating the macronutrient prescription. Conversely, around one-quarter of respondents (24%) reported aiming to meet only the lowest safe intake of protein, consistent with more traditional, ratio-driven approaches to CKD.

3.4.5. Carbohydrate

In KDT, the term 'net carbohydrates' is frequently used, but definitions vary internationally. In clinical practice, net carbohydrates are most commonly defined as the total carbohydrate content minus fiber, and in some cases, minus some or all sugar alcohols, which have minimal digestible carbohydrate and glycaemic affect (Table 3).

Table 3. Definitions of ‘net carbs’ used in ketogenic diet therapy: survey responses

Definition of ‘net carbs’	Agreement rate (% survey respondents)
Total carbs minus fiber	40%
Total carbs minus fiber and all sugar alcohols	9%
Total carbs minus fiber and 50% sugar alcohols, except erythritol which is 10% of carbs	7%
Total carbs minus fiber and 50% sugar alcohols, except erythritol which is 10% of carbs, and minus 10% monk fruit or allulose	5%

The relevance of this distinction depends heavily on national food labelling regulations. In countries such as the United States and Canada, fibre and sugar alcohols are included in the total carbohydrate count on nutrition labels. In contrast, food labelling regulations in the United Kingdom, Europe, and Australia exclude fiber from the total carbohydrate content, and therefore the term “net carbohydrate” is less commonly used.

For clarity and consistency, all references to carbohydrate within this document refer to net carbohydrates, as defined by the prescribing clinician or local practice.

In CKDs, carbohydrate intake is typically calculated after determining the ketogenic ratio and protein requirements. The remaining caloric allowance is allocated to carbohydrate, maintaining the specified fat-to-non-fat ratio. The exact number of grams will therefore vary based on the energy prescription and dietary ratio used.

3.4.5.1. Carbohydrate – other sources

For patients receiving modified texture diets (across any type of KDT), 60% of survey respondents reported using low-carbohydrate thickeners, such as gum-based thickeners. 26% count starch-based thickeners within the daily carbohydrate allowance, while 26% only count thickeners when clinically indicated – for example, if ketones are sub-optimal. A small proportion (5%) reported never counting either gum- or starch-based thickeners in the prescription.

Medications and supplements can contain carbohydrates, particularly oral solutions, suspension, and chewable tablets, which may contribute significantly to the total carbohydrate intake. If not accounted for, this can impair ketosis or require further restriction of dietary carbohydrate.

Clinical approaches to managing carbohydrate from medications vary:

- engage with the pharmacy team to review and change medications to low-carbohydrate versions (typically tablets or capsules instead of oral solutions or chewable tablets) before initiating KDT
- include the carbohydrate from medication as part of the KDT prescription (the diet plan may require re-calculation if the dosages are significantly altered)
- do not count the carbohydrate from medication and continue with the usual diet prescription, particularly if doses are small or carbohydrate is unavoidable

Survey data were not collected on which of these strategies are most commonly adopted in practice.

3.4.6. Fluid

Historically, fluid prescriptions for CKD ranged from 80% to 100% of estimated daily requirements²⁵. More recent guidance indicates that fluid restriction is not beneficial and may, in fact, be counterproductive⁸. Maintaining adequate hydration is essential for preventing constipation, supporting metabolic processes, and reducing the risk of nephrolithiasis, particularly in patients taking carbonic anhydrase inhibitors, such as topiramate or zonisamide.

Survey data reflected broad agreement with current recommendations. Ninety-six percent (96%) of respondents reported prescribing fluids to meet 100% of estimated fluid requirements in CKD protocols. This near-unanimous consensus supports the shift away from historical fluid restriction practices. Fluid needs may be determined using country-specific age- and weight-based equations, or by continuing the patient’s pre-KDT fluid intake if clinically appropriate. The method of calculation varies between centres, depending on local protocol and clinician preference.

3.4.7. Micronutrient supplementation

The restricted nature of KDT significantly alters the intake of vitamins, trace minerals, and electrolytes compared to a well-planned traditional diet^{26,27}. Micronutrient deficiencies are most commonly reported in individuals following CKDs²⁸⁻³¹. Documented deficiencies include thiamine, folate, pantothenic acid, calcium, phosphorus, iron, vitamin D, Vitamin C, selenium, ferritin, and magnesium, as well as carnitine (a conditionally essential amino acid, not a micronutrient). Several case reports of scurvy have been published in individuals on CKD who were not receiving adequate vitamin C supplementation^{31,32}. Selenium deficiency has also been reported in children on CKD²⁸, and has been associated with impaired myocardial function³³. One study found selenium levels declined after 6 and 12 months on CKD, prompting recommendations for close monitoring²⁹, although it remains unclear whether selenium supplementation beyond standard multivitamin is necessary⁹. It is generally accepted that the more restrictive the ketogenic diet, the greater the risk of micronutrient deficiencies.

To prevent micronutrient deficiencies, optimal clinical management recommendations are to provide a complete carbohydrate-free multivitamin and mineral supplement for individuals on KDT. This should include, at a minimum, selenium, calcium and vitamin D⁹.

If a carbohydrate-free formulation is not available or tolerated, the carbohydrate content of an alternative supplement should be included in the overall dietary prescription. Supplementation should be aligned with age-specific recommended daily intakes, taking into account the individual's dietary intake and any contributions from commercial ketogenic products or formula feeds.

In addition to preventing deficiencies, some micronutrients may play a role in mitigating the adverse effects of KDT. Particular attention should be given to calcium and vitamin D, as individuals on KDT can be at increased risk of acidosis and impaired bone health, including reduced bone mineral density and osteoporosis³⁴.

3.4.7.1. Survey results

In clinical practice, 95% of survey respondents reported being responsible for advising on micronutrient supplementation for patients on CKD. The majority (91%) routinely prescribed multivitamin and mineral supplements, either as standard practice or based on diet analysis. The most commonly prescribed specific supplements were carnitine when a deficiency was identified (52%), calcium (44%), and vitamin D (35%). Routine use of carnitine, zinc, or selenium – regardless of deficiency status – was less common, each reported by 5-9% of respondents. Potassium citrate was prescribed prophylactically by 25% of respondents and in cases of hypercalciuria by 13%. Sodium bicarbonate was routinely supplemented by 5%, and used for the management of acidosis by 20%.

3.5. Special dietary requirements

With appropriate planning and professional support, most special dietary requirements can be accommodated within KDT. This includes dietary restrictions related to food allergies, intolerances, cultural or religious practices, and personal preferences such as vegetarianism or veganism.

When adapting a ketogenic diet to meet these needs, particular attention should be given to micronutrient adequacy, as food substitutions may reduce the variety or nutrient density of the diet. Vitamin and mineral supplementation should be reviewed and adjusted accordingly to prevent deficiencies.

It is important to obtain a detailed history of not only the patient's dietary requirements, but also any allergies or restrictions within the household, as these may affect food preparation, safety, and adherence to the prescribed diet.

Families may benefit from a tailored list of ingredient substitutions that are suitable for their dietary needs—for example, dairy-free, egg-free, or vegan alternatives. A summary of commonly used ketogenic ingredients and suggested substitutions is provided in Table S2.

3.5.1. Survey results

To support the success of vegetarian or vegan KDT, respondents reported using a range of strategies. The most common was the incorporation of MCT-enriched products, used by 60% of respondents. Commercial ketogenic formulas and protein powders were each reported by 36% of respondents as useful tools. Additionally, 27% allowed a more liberal carbohydrate allowance, and 22% allowed greater flexibility in protein targets, to accommodate plant-based sources that may contain both protein and carbohydrates.

Several practitioners also commented that when working with vegan families, they advised prioritising 'pure' fat sources—such as oils—over processed plant-based fat alternatives (e.g., vegan spreads or creams), which may contain added carbohydrates or protein and could reduce the diet's ketogenic potential.

For patients requiring allergen-safe ketogenic diets, similar strategies were reported. Use of MCT oils or MCT-containing products was the most common approach, used by 51% of respondents. Commercial ketogenic formulas were used by 44%, while 19% relied on protein powders. Where needed, 13% allowed a more liberal carbohydrate limit, and 14% adjusted protein targets to support adequacy and tolerability in the context of food allergies or intolerances.

3.6. Meal planning

Translating a ketogenic diet prescription into a practical and sustainable meal plan is a crucial component of dietary implementation. While formats may vary between centres, meal plans are most commonly provided as macronutrient targets for each meal or snack, enabling families to structure their food intake around the prescribed fat, protein, and carbohydrate allowances. Sample meal plans and recipe examples are provided in Tables S3, demonstrating typical approaches for CKD prescriptions.

3.7. Enteral nutrition

Enteral nutrition is a common and effective method for delivering KDT, particularly for individuals who are unable to meet their nutritional needs orally. CKD are most frequently used in this context⁸, and can be administered via nasogastric, gastrostomy, or jejunostomy tubes. The literature supports both the efficacy and adherence of CKD in enterally fed patients. In a study by Kossoff et al.³⁵, 59% of children who were exclusively tube-fed achieved over 90% seizure reduction at 12 months. Similarly, Hosain et al.³⁶ reported high levels of compliance in this population.

A variety of commercial ketogenic formulas are available to support enteral feeding, including both liquid and powdered preparations (Table S4). The availability, composition, and prescribing processes for these products vary by country. Formulas can be used as a sole source of nutrition or combined with other products to meet the patient's individual energy and nutrient needs.

CKD can also be delivered using blended ketogenic diets (BKDs), which involve liquefying food or drink to a suitable consistency for tube feeding^{37,38}. Recipes for BKDs are typically developed in the same way as for oral diets, with adaptations for texture and viscosity. An example BKD recipe is provided in Table S3.

3.7.1. Survey results

Survey findings reflected widespread use of KDT in enterally fed patients. The majority of respondents (91%) reported using a sole-source complete nutrition formula for patients without allergies receiving enteral ketogenic diets. These formulas provide all necessary macronutrients and micronutrients in a pre-prepared format, simplifying administration and reducing preparation burden for families and healthcare teams.

However, many centres reported using more flexible or tailored approaches where appropriate. To meet individual nutritional needs and accommodate clinical considerations, 43% of respondents reported combining modular components or blended foods with commercial ketogenic formulas. Additionally, 40% of respondents reported using home-prepared blended whole foods, and 21% used commercially available blended ketogenic formulas.

For patients with cow's milk protein allergy who require enteral feeding, a broader range of strategies is employed.

Modular components were the most commonly used approach, reported by 52% of respondents. Other frequently used options included ketogenic peptide-based formulas (41%), blended whole foods (40%), plant-based ketogenic formulas (36%), and commercial blended ketogenic formulas (14%).

These findings highlight the adaptability of enteral ketogenic diet provision across clinical settings, with practices tailored according to product availability, nutritional requirements, allergy status, and local expertise.

3.8. Parenteral nutrition

Parenteral nutrition (PN) may be indicated in clinical situations where enteral feeding is not possible and bowel rest is required – such as gastrointestinal complications or severe illness³⁹. Ketogenic Parenteral Nutrition (KPN) may be required when it is necessary to maintain ketosis during periods of enteral feeding interruption. KPN is not recommended in preterm infants or malnourished children, due to elevated risk of further malnutrition, metabolic instability, and associated complications⁴⁰. Where KPN is considered, it must be undertaken by a team with specialist expertise in KDT, and only following comprehensive medical and nutritional assessment. The goals of therapy should be clearly defined, and the potential benefits weighed carefully against the associated risks.

Formal guidance on the implementation of KPN has been published elsewhere⁴⁰ and teams considering its use should refer to this literature to inform clinical decision-making and protocol development.

3.9. Prescribable ketogenic products

Prescribable ketogenic products are commonly used in CKDs to support the diet. These products may be used alongside oral food intake to increase daily fat consumption, modify the type of fat used, and improve intake of protein, vitamins, and minerals⁴¹. They can be particularly useful in managing complex prescriptions or supporting dietary variety.

In addition to prescribable items, a range of non-prescribable products—such as low-carbohydrate baking mixes, cereals, and snacks—may also be suitable for individuals following KDT. The choice of product should be individualised and based on factors including the patient's age, energy requirements, ketogenic ratio, presence of food allergies or intolerances, and any needs for plant-based or texture-modified diets.

All prescribable and specialty food products used in KDT should be counted within the diet prescription, and their use should be monitored and moderated to maintain dietary balance and therapeutic efficacy.

3.9.1. Survey results

According to survey responses, 84% of dietitians offer commercial ketogenic formulas to orally fed patients on KDT, although these are not always used routinely. The availability, prescribing process, and formulation of these products vary between countries and healthcare systems. An outline of commonly used prescribable ketogenic products is provided in Table S4.

Medium-chain triglyceride (MCT) products are widely used as part of KDT protocols, with 87% of survey respondents reporting their inclusion. Most respondents (78%) reported prescribing or increasing MCTs in millilitre volumes, adjusting according to clinical goals and tolerance.

When asked about the regulation of keto-specialty food products, 69% of respondents stated they only restrict these items if they are found to negatively affect ketosis or seizure control. A small proportion (7%) reported limiting such products during the first month of treatment, while 6% reported always applying limitations, depending on the individual patient.

3.10. Diet initiation

3.10.1. Classical ketogenic diets

Historically, CKDs were initiated in an inpatient setting and preceded by a period of fasting, typically lasting between 12 and 24 hours. However, both the literature and current clinical practice no longer support this approach. A large majority of survey respondents (96%) reported that fasting is not required for effective CKD initiation, a position consistent with findings in the literature suggesting that gradual initiation leads to fewer adverse effects without compromising dietary efficacy^{42,43}. As a result, most children and young people can now begin CKD at home, reducing disruption to family life and the need for hospitalisation. Exceptions include infants under 1 year of age⁴⁴ and medically complex patients, for whom inpatient monitoring may still be appropriate.

In practice, some clinicians do not aim to immediately reach a specific target ketogenic ratio. Instead, they may adopt a more incremental approach—starting at a lower ratio or a percentage of fat and gradually increasing it over time. This ‘low and slow’ methodology⁴⁵ allows for ongoing review of clinical response, ketone levels, and dietary tolerance, facilitating a more personalised and tolerable initiation process.

3.10.1.1. Survey results

In clinical practice, the majority of practitioners (79%) report gradually increasing the CKD ratio during the initiation phase, typically progressing from a 1:1, to a 2:1, and then 3:1 ratio. Some practitioners described using smaller incremental steps (e.g. increases of 0.2 to 0.5) based on patient tolerance and response. Adjustments to the ratio are generally made in response to ketone levels and clinical efficacy. A smaller proportion of respondents (15%) initiate CKD by introducing the full dietary prescription one meal at a time. The remaining respondents described using a flexible or combined approach, adapting the method to suit the individual needs and preferences of the patient or family.

The duration of the initiation process was noted to depend largely on the clinical setting. For those initiating the diet in an inpatient setting, more than half of respondents (55%) aim to establish ketosis—defined as ketone levels above 2 mmol/L—within three to four days. Some respondents reported using faster or slower initiation protocols tailored to specific clinical scenarios or patient needs.

When initiating CKD via enteral nutrition, most practitioners start with a ketogenic ratio of 1:1 or 2:1 and gradually increase the ratio depending on the degree of ketosis and seizure control achieved. Two in five respondents follow this stepwise approach. An alternative strategy, used by 10% of respondents, involves incrementally substituting the patient's usual enteral formula with a ketogenic formula—typically in steps such as one-quarter, one-half, three-quarters—until the full prescription is in place. A further 38% of respondents reported using a combination of both methods.

Example initiation protocols for both oral and enteral CKD are provided in Tables S5 and S6, respectively.

3.11. Home monitoring

3.11.1. Ketones

Monitoring ketone levels at home can be a useful marker to assess whether the dietary prescription is sufficient to induce and maintain therapeutic ketosis. It may also guide any necessary dietary adjustments.

Ketones can be measured via urine (detecting acetoacetate) or blood (detecting beta-hydroxybutyrate, BHB).

Urine testing is less invasive and more widely accessible but tends to be less accurate, as results may be affected by hydration status and do not reflect real-time ketone levels⁴⁶. Nevertheless, urine ketone testing remains a practical option for home monitoring and, when used, should be performed several times per week⁹. Blood ketone testing provides a more accurate reflection of current metabolic state and can be performed both in clinical settings and at home using glucose meters compatible with ketone strips. BHB levels have been shown to correlate more closely with seizure control than urine ketones^{47,48}. Urine ketone levels of 3–4+ (approximately 8–16 mmol/L) typically correspond to blood ketone levels of around 2 mmol/L. Blood ketone concentrations exceeding 3 mmol/L, and in some cases 4 mmol/L, may be most effective for seizure reduction, although the literature remains inconclusive^{47,49,50}. In infants, routine blood ketone monitoring is recommended to identify potential excess ketosis and mitigate risks in this vulnerable population⁴⁴.

3.11.1.1. Survey results

In clinical practice, the majority of survey respondents (86%) report using blood ketone monitoring when initiating CKDs, with 70% recommending that BHB be tested twice daily. More than half (54%) advise reducing or discontinuing ketone monitoring once levels stabilise, while 23% recommend doing so once treatment goals are achieved. For long-term monitoring at home, 41% of practitioners rely on urinary ketone testing, supplemented with blood BHB measurements as needed—either at home or during routine clinic visits.

In addition to routine monitoring, 89% of respondents recommend checking ketones in the event of symptoms of hyperketosis. Other commonly cited indications include loss of seizure control (88%), signs of illness (66%), and before or after physical activity (14%).

Target ketone ranges vary across practices and are often individualised. However, it is common for clinicians to aim for blood BHB levels between 2–6 mmol/L and urinary acetoacetate levels between 8–16 mmol/L (personal communication with study authors).

3.11.2. Glucose

Due to the low carbohydrate content of KDT, there is a recognised risk of hypoglycaemia, particularly during the initiation phase or during episodes of illness. While this is a known concern, published reports suggest that hypoglycaemia is rare, with most cases occurring in infants receiving CKD⁵¹⁻⁵⁴. Nonetheless, careful monitoring during initiation—especially in younger or medically complex children—is recommended to identify and manage any episodes of low blood glucose promptly.

3.11.2.1. Survey results

Survey responses highlighted that glucose monitoring is common practice when initiating CKD, particularly in inpatient settings. Ninety-four percent of respondents monitor glucose levels during inpatient initiation, with continued monitoring typically maintained until glucose levels are considered stable (26%). One-fifth of practitioners continue glucose checks until the full dietary prescription or target ratio is reached, while smaller numbers perform intermittent testing every 2–5 days (6%), weekly (6%), or every one to two weeks (8%). There was limited experience reported with continuous glucose monitoring outside of intensive care units.

In outpatient settings, 44% of respondents recommend twice-daily glucose monitoring at initiation, while 14% recommend daily monitoring and 12% either do not recommend routine glucose checks or advise testing only in response to hypoglycaemia symptoms. Twenty-two percent of respondents continue outpatient glucose monitoring until levels stabilise, with others advising continuation until ketone levels stabilise (14%) or until the full prescription is reached (14%).

Definitions of hypoglycaemia varied between centres. The most commonly cited thresholds were <3.0 mmol/L (23%) or <2.5 mmol/L (19%), while other respondents used thresholds of <50 mg/dL (18%) or <40 mg/dL (11%).

In the event of hypoglycaemia, most practitioners recommend rapid intervention. Three-quarters (77%) advise a specific volume of sugar-sweetened beverage, 41% recommend a defined quantity of carbohydrate in grams, 33% use a commercial carbohydrate modular product, and 31% report use of intravenous dextrose. From survey comments, the most commonly suggested oral or enteral intervention was 3–5 grams of carbohydrate, often provided as 30–50 ml of fruit juice.

3.12. Follow-up

Optimal clinical management guidelines recommend that children aged over one year should receive a clinical review, including laboratory monitoring, at one month after initiation, followed by reviews at 3, 6, 9, and 12 months⁹. After the first year, follow-up visits typically occur every six months. Between visits, regular communication with the dietetic team—via telephone or email—is strongly encouraged to monitor progress and address issues promptly. For infants under one year of age, more frequent and intensive follow-up is advised due to their rapid developmental changes and heightened nutritional vulnerability⁹.

Each follow-up appointment should involve a multidisciplinary assessment of clinical and nutritional status. This includes review of serum and urine biochemistry, evaluation of growth parameters (height, weight, BMI, and head circumference in infants), and assessment of adherence to the diet. Nutritional status should be assessed in the context of growth velocity and ideal weight for stature, with consideration of whether the current KDT prescription remains appropriate. Supplementation with vitamins and minerals should also be reviewed and adjusted if necessary.

Nutritional assessments at follow up should include (adapted from optimal clinical management recommendations⁹):

- Height, weight, ideal weight for stature, growth velocity, BMI when appropriate
- Head circumference in infants
- Review appropriateness of KDT prescription
- Review vitamin and mineral supplementation
- Assess compliance to KDT
- Adjust KDT if necessary to improve compliance, seizure control and/or nutritional status

Psychosocial factors identified during pre-diet preparation—such as family support, cultural considerations, and educational needs—should also be revisited during follow-up, as these may impact long-term adherence and outcomes.

If non-adherence is identified or suspected, a number of strategies can be considered to improve engagement and dietary success. These include practical interventions such as teaching kitchens or cooking demonstrations^{16,55}, use of ketogenic applications or calculators^{19,56,57}, trial of alternative dietary regimens such as LGIT^{56,58,59}, and leveraging digital communication tools (e.g. email, WhatsApp) to maintain regular contact and reinforce support between visits⁶⁰.

3.12.1. Survey results

Survey responses indicate broad alignment with optimal clinical management recommendations for follow-up practices. The majority of practitioners (88%) monitor gastrointestinal health and non-seizure benefits—including cognition and quality of life (72%)—as part of routine follow-up. Satiety is also reviewed by two-thirds of respondents (66%), reflecting an emphasis on the holistic impact of the ketogenic diet beyond seizure control.

In assessing adherence to KDT, ketone levels are the most widely used indicator, with 93% of respondents relying on blood or urinary ketones to gauge dietary compliance. Verbal discussions during clinic appointments or phone calls are also common (91%), with food diaries used by 62% of practitioners. A smaller proportion (12%) make use of formal questionnaires to support their assessment.

Medication weaning decisions vary between centres but are most commonly considered when seizure control is achieved (69%). A third of respondents (33%) indicated that they also consider tapering medication if there is a risk of adverse interactions between antiepileptic drugs and KDT. Timelines for initiating medication reduction vary: 29% consider weaning after three months on diet, 13% after six months, and 10% as early as six weeks, depending on clinical response and practitioner judgement.

3.12.2. Telehealthcare

Telehealthcare has become an increasingly valuable tool in the maintenance of ketogenic diet therapy (KDT), particularly following its expanded use during the COVID-19 pandemic⁶⁰⁻⁶². While not universally appropriate, it can offer enhanced flexibility and accessibility for families, especially those living at a distance from specialist centres. However, careful consideration should be given to both the advantages and disadvantages of telehealth (outlined in Table S7) when determining its suitability for individual patients and at specific stages of their treatment journey.

There are no changes to the recommended frequency or content of clinical reviews when delivered via telehealth. With appropriate planning, a tailored approach, and support from an experienced multidisciplinary team, KDT can also be successfully initiated remotely for selected patients and families⁶⁰⁻⁶². This flexibility supports continuity of care and broadens access to ketogenic services, while maintaining clinical safety and effectiveness.

3.12.2.1. Survey results

In clinical practice, telehealthcare is commonly used to support ketogenic diet therapy (KDT), particularly for patients and families who live far from the clinical centre. Over half of survey respondents (62%) reported using telehealth for this reason, while others (23%) indicated it was used as an adjunct for patients requiring additional support. A third of practitioners (32%) use video consultations for all patients, while 39% reported using them specifically for monitoring or review appointments between face-to-face visits. Additionally, 37% offer video appointments on an as-needed basis, and 14% use video for all clinic appointments except for rare instances when in-person assessment is necessary. Thirteen percent conduct one face-to-face consultation per year, with all other appointments held remotely.

In addition to video appointments, other forms of remote communication were widely adopted. Telephone contact was the most commonly used (93%), followed by email (80%). Some teams used messaging through electronic medical charts, online personal health records or apps (14%), while others reported providing support via patient support groups (13%), educational videos (13%), newsletters (6%), or messaging services such as WhatsApp (11%).

3.13. Fine-tuning the diet prescription

Fine-tuning of the ketogenic dietary prescription is an important part of clinical care, allowing practitioners to optimise therapeutic ketosis, improve treatment efficacy, and minimise adverse effects. While often associated with the initial trial or adjustment period, fine-tuning can be required at any stage during treatment. Adjustments may include changes to macronutrient ratios, energy intake, fluid targets, or supplement use, and are typically informed by clinical response, ketone levels, side effects, and patient or family feedback. Evidence from Selter et al. demonstrated that fine-tuning led to improved seizure control in 18% of patients already responding to CKD, with 3% achieving seizure freedom following adjustments⁶³.

3.13.1. Survey results

According to our survey, changes to the KDT prescription are most commonly made by the dietitian (69%), or jointly with the wider ketogenic team (20%). In a smaller number of cases (7%), adjustments are led by the medical doctor. The primary driver for fine-tuning the prescription is seizure control, cited by 95% of respondents. This is followed by ketone levels (70%) and achieving a specific macronutrient ratio or prescription (52%). Survey comments also highlighted the importance of factors such as dietary adherence, acceptability and tolerance, glucose levels, growth, behaviour, and changes in weight. Most practitioners (88%) reported that they consider liberalising the dietary prescription as the patient gets older. This is usually based on clinical diagnosis and progression, the stability of ketosis, duration on the diet, and adherence over time.

3.13.1.1. Fat

Adjustments to fat intake within a KDT prescription are primarily driven by the need to optimise ketosis, manage side effects, and improve seizure control. The majority of survey respondents reported that fat content is modified based on ketone levels (90%), gastrointestinal side effects (90%), and seizure control (81%). Other influencing factors include the presence of hyperlipidaemia (reported by 77% of respondents), weight change (59%), and the need to improve dietary adherence (57%). To a lesser extent, changes in blood glucose levels (23%) and linear growth (21%) may also guide fat prescription adjustments.

MCTs are commonly used to support fine-tuning of KDT, as their metabolism yields more ketones per gram than LCTs, owing to their rapid absorption and hepatic conversion. Ninety-five percent of practitioners reported using MCT as part of this process, most frequently when ketone levels are suboptimal or inconsistent (96%), or when further restriction of carbohydrate is poorly tolerated (48%). Based on survey comments, MCT is typically prescribed up to 30–50% of total calories in CKD, depending on individual tolerance and clinical judgement. Introduction is often gradual due to the risk of gastrointestinal side effects, including abdominal discomfort, loose stools, nausea, and vomiting⁶⁴.

3.13.1.2. Carbohydrate

Carbohydrate intake is often adjusted during KDT to improve efficacy, metabolic control, and diet tolerability. According to our survey, the most common reason for modifying carbohydrate prescription is to address suboptimal ketone levels, cited by 89% of respondents. Adjustments may also be made when seizure control or other treatment goals are not being met (69%), or to support better blood glucose regulation (82%). Improving adherence to the diet is another key driver (72%), as is the need to mitigate adverse effects such as gastrointestinal discomfort or poor appetite (61%). In some cases, carbohydrate is adjusted in response to weight changes (38%) or concerns about linear growth (23%).

When fine-tuning carbohydrate intake, it is important to account for non-nutritive sources that may influence ketone production. Ingredients such as sugar alcohols—commonly found in low-carbohydrate or ‘keto’ food products, drinks, and some liquid medications—can impact ketosis and should be included in dietary assessments.

3.13.1.3. Protein

Protein prescriptions in KDT are adjusted based on a range of clinical indicators and patient needs. Survey results show that the most common reason for modifying protein intake is to support linear growth, cited by 73% of respondents. Suboptimal ketone levels are also a factor (50%), as are laboratory markers such as low serum urea or abnormal amino acid profiles (59%). Adjustments may also be made to improve dietary adherence (51%), respond to lack of efficacy in terms of seizure control or other clinical goals (33%), or address weight changes (54%). Less commonly, adverse effects (24%) and blood glucose levels (18%) influence the decision to amend protein targets.

In children receiving CKD via enteral nutrition, the choice of protein source may also be considered. For example, using whey-based formulas instead of casein-based ones can be beneficial in managing reflux symptoms⁶⁵.

3.14. Adverse effects

Potential adverse effects associated with KDT are detailed in published optimal clinical management recommendations⁹. Gastrointestinal symptoms are the most frequently reported side effects during the early stages of treatment and are typically short-lived or manageable through dietary modifications and, if necessary, medical intervention. In the short term, individuals on CKD may also experience alterations in micronutrient status or episodes of hypoglycaemia^{27,54}. Over the longer term, more serious complications can arise, including hyperlipidaemia, renal calculi, reduced bone mineral density, hypercalciuria, growth concerns, cardiac abnormalities, and in rare cases, pancreatitis^{9,66}. These adverse effects require careful monitoring and multidisciplinary management. While medical oversight is essential, adjustments to the ketogenic diet can play a role in mitigating some of these risks. A range of potential dietary strategies for addressing persistent symptoms and adverse effects is summarised in Table 4.

Table 4. Dietary adjustments for individuals on ketogenic diet therapy with specific symptoms / adverse effects

Symptom	Considerations	Strategies (% of survey respondents who selected each strategy)
High ketone levels and/or acidosis	- Is calorie intake sufficient / weight gain appropriate? - Any recent weight loss? - Any missed meals or feeds? - Any delay in meals or feeds? - Any recent changes in ingredient brands used? - Any recent changes in medication? - Any signs of illness? - Evaluate fluid intake/dehydration - Evaluate which fat sources are being used	- Increase carbohydrate intake (80%) - Reduce fat intake (73%) - Increase fluid intake (54%) - Start bicarbonate (38%)
Low ketones	- Is calorie intake too high / is there rapid weight gain? - Is protein intake excessive? - Check adherence to diet prescription - Check if there are any recent change in products or ingredient brands - Any signs of illness? - Any recent changes in medication? - Any changes in family situation / routine / travel? - Any pattern as to which time of day ketones are lower/higher? - Any change to bowel habits? Constipation can slow digestion and impact ketosis.	n/a (not asked in survey)

Symptom	Considerations	Strategies (% of survey respondents who selected each strategy)
Recurrent hypoglycemia	• Check adherence to diet prescription • Check for any changes in activity levels • Check for patterns of hypoglycemia • Evaluate frequency of meals/snacks • Check for level of ketosis • Check energy intake and growth • Evaluate feed dilution, where applicable	• Increase carbohydrate intake (86%) • Increase daily calories (58%) • Decrease fat intake (28%) • Provide a specified amount of sugar-sweetened beverage or commercial carbohydrate modular component every time hypoglycemia occurs (20%) • Increase protein intake (18%)
Diarrhea	• Any new medications recently started, in particular antibiotics? If so, could this be linked? • Any new foods/ingredients/fat sources introduced recently? • Consider feeding rate (enteral feeders) • Check adherence to diet prescription • Check food portion or feed volume • Check for history of constipation, as could be overflow diarrhea • Evaluate signs of steatorrhea • Consider bacterial overgrowth as a potential differential	• Reduce MCT (86%) • Supplementation with probiotics (60%) • Increase fluid intake (57%) • Reduce fat intake (41%) • Lower diet ratio / liberalize diet prescription (39%) • Decrease fiber from food (33%) • Supplementation with modular fiber (29%) • Increase fiber from food (26%)
Vomiting	• Check for excess ketosis or hypoglycemia • Any new foods/ingredients introduced recently? • Consider feeding amount and rate (enteral feeders) • Check adherence to diet prescription • Check food portion or feed volume • Consider reflux and/or constipation	• Lower diet ratio / liberalize diet prescription (76%) • Reduce fat intake (56%). • Oral rehydration solution mixed with water (44%) • Increase fluid intake (34%) • Provide electrolyte solution (33%) • Suggest periods of fasting (18%) • Other (27%), for example, consider constipation or reflux, look at timings and volume of meals, trial a peptide formula if applicable.
Constipation	• Check fluid intake • Check fiber intake • Evaluate usual bowel habits • Consider recommending smaller meals • Chronic constipation should be discussed with the medical team to consider treatment options	• Increase fluid intake (96%) • Advise on fiber-rich food sources (80%) • Add MCT (58%) • Supplementation with modular fiber (49%) • Supplementation with probiotics (40%) • Supplementation with magnesium citrate (23%) • Offer prune juice (8%) [consider amount required without impacting ketone/glucose levels or seizure control]

Symptom	Considerations	Strategies (% of survey respondents who selected each strategy)
Reflux	- Evaluate pattern of symptoms - Check food portion or feed volume - Consider enteral feeding pattern or rate - Consider types of fat - Consider constipation - Is reflux optimally medically managed, if applicable?	- Sit upright when eating/feeding (91%) - Smaller meals / feeds (91%) - Reduce fat intake (53%) - Lower diet ratio / liberalize diet prescription (47%) - Consider introduction of a thickener (34%) - Ginger tea (11%) - Decrease calories (9%)
Hyperlipidemia	- Were laboratory measures taken in a fasted state? - Dietary assessment to identify current fat sources - Check carnitine levels - Consider that, in many cases, lipid values will stabilize or normalize without intervention within approximately 12 months - In cases of persistent hyperlipidemia, referral to the metabolic team may be required for genetic testing and/or further investigation	- Advise on alternative fat sources (94%) - Add MCT (60%) - Lower diet ratio or liberalize diet prescription (46%) - Other (19%), for example, encourage food sources of soluble fiber, add plant stanols - Stop KDT (6%)
Hypercalcemia or hypercalciuria	- Assess fluid intake (increased hydration is recommended for individuals with hypercalcemia, with calcitonin as the next therapeutic option⁷⁶) - Assess calcium intake - Review level of ketosis - Consider Citrate supplementation - Consider contributing factors, including carbonic anhydrase inhibitors - Consider referral for medical support, if persistent	- Increase fluid intake (63% re. hypercalcemia / 70% re. hypercalciuria) - Refer to renal specialty (50% / 51%) - Lower supplement dose (49% / 40%) - Add a citrate (38% / 48%) - Lower diet ratio or liberalize diet prescription (37% / 40%)

3.15. Management of illness

During episodes of intercurrent illness, dietary adjustment may be necessary to maintain ketosis and reduce the risk of seizure recurrence. In such cases, a ketogenic 'milkshake' tailored to the individual's prescription can be used as a temporary meal replacement, and may be diluted if poorly tolerated⁶⁷. Close monitoring of both blood glucose and ketone levels is advised, as the risk of hyperketosis or hypoglycaemia is heightened during illness, particularly if dietary intake is reduced⁶⁷.

As with any unwell child, medical advice should be sought if there are concerns or the illness persists, to ensure appropriate treatment is provided. Ideally, medications—including antibiotics—should be in low-carbohydrate formulations. However, if no suitable alternative is available, the medication should not be withheld; treating the underlying illness must take priority. If long-term treatment with carbohydrate-containing medication is required and ketosis is affected, the dietary prescription may need to be temporarily adjusted.

Maintaining hydration is also a priority. Sugar-free fluids should be encouraged, and if needed, rehydration solutions can be used in diluted form to avoid exceeding the individual's carbohydrate allowance. These may help prevent hyperketosis and/or acidosis, particularly in children who are unable to tolerate full meals. If vomiting or diarrhoea occurs, a temporary reduction in fat intake—particularly MCT—may be necessary. This can be achieved by adjusting the diet prescription or offering half-sized meals or feeds.

If the child is nil by mouth for over 12 hours, such as in preparation for surgery, it is advisable to check whether the anaesthetic team has access to a ketogenic protocol⁶⁸. During this time, ketone and blood glucose levels should be monitored more frequently (every 4 hours is recommended) to reduce the risk of hypoglycaemia or excessive ketosis. The diet should be reintroduced as soon as the child is able to tolerate food again. If intravenous fluids are required, non-dextrose-containing solutions should be used, unless dextrose is necessary to manage acute hypoglycaemia or hyperketosis⁶⁷. Studies have shown that children on KDT undergoing general anaesthesia with carbohydrate-free intravenous fluids maintained stable glucose levels; however, some experienced metabolic acidosis⁶⁸. As such, serum pH or bicarbonate levels should be monitored during prolonged procedures. If oral or enteral feeding must be withheld for more than 48 hours, PN may be considered^{40,69}.

3.15.1. Survey results

In the event of illness, survey respondents reported several common strategies to support patients while maintaining dietary goals. The overwhelming majority (93%) prioritise maintaining adequate fluid intake during illness. Many also reported adapting meal formats to improve tolerability: 78% offer smaller meals or feeds, and 57% recommend the use of oral rehydration solutions to support hydration and electrolyte balance. Just over half of respondents (51%) use ketogenic meal replacement shakes, tailored to the individual's diet prescription, as a temporary alternative when full meals are not tolerated. A smaller proportion (21%) reported offering meals or feeds without added fats, i.e. not fully within the ketogenic diet prescription, to help manage intake during periods of gastrointestinal upset or reduced appetite.

3.16. Diet discontinuation

3.16.1. When to consider discontinuing KDT?

The decision to discontinue KDT should be made on an individual basis, involving shared discussion between the child (where appropriate), their parents or carers, the dietitian, and the neurologist. As a medical therapy, KDT carries the risk of adverse effects and should not be continued if treatment goals are not being achieved. Evidence suggests that 75% of children who will respond to KDT do so within the first 14 days⁷⁰, though some may take longer (up to two months or more) to show benefit. Optimal clinical management recommendations advise discontinuing the diet after approximately three months if there has been no reduction in seizures or other therapeutic benefits⁹.

For individuals who do respond well—typically defined as achieving a seizure reduction of 50% or more—discontinuation is often considered after around two years of treatment⁹. However, there is no defined maximum duration for KDT⁹ and long-term use has been documented for up to 20 years in individuals experiencing significant seizure control with minimal side effects^{71,72}. In certain cases, longer treatment durations may be appropriate. For example, children with epileptiform discharges on EEG, focal abnormalities on MRI, or a diagnosis of tuberous sclerosis may benefit from extended therapy due to a higher risk of seizure recurrence⁷³. Additionally, for individuals with GLUT1 deficiency syndrome (GLUT1-DS), it is recommended that the diet be continued at least until puberty⁹ or into adulthood⁷⁴. In those with pyruvate dehydrogenase deficiency (PDHD), extended use beyond two years may also be appropriate depending on response and tolerability⁹.

3.16.2. How to discontinue KDT?

Discontinuation of KDT should be carefully planned and individualised based on patient response, clinical condition, and the duration of therapy. A retrospective review suggested that a gradual weaning period of 4–6 weeks is both feasible and well tolerated in most cases⁷⁵. For infants on CKD, the ratio should be slowly reduced^{44,76} until ketones are no longer present. A complete wean within two weeks may be considered for infants who have derived no clinical benefit from the diet⁴⁴.

Once ketone levels fall—typically defined as <1 mmol/L (<20 mg/dL) or <0.5 mmol/L (<5 mg/dL)—the transition back to the child's usual diet can be accelerated^{44,73,76}. If seizure control deteriorates during discontinuation, many patients can regain seizure stability through dietary or anti-seizure medication adjustments^{73,75}. In such cases, practitioners may opt to pause the weaning process for 3–7 days, reassess clinical response, and then resume at a slower pace. Alternatively, returning temporarily to the previous, better-tolerated dietary prescription before resuming the wean may be helpful. In all cases, medical input is recommended if seizure frequency increases. According to optimal clinical management recommendations, micronutrient supplementation should be continued until KDT is fully discontinued⁹.

3.16.2.1. Survey results

Survey responses indicate that the length of time taken to discontinue ketogenic diet therapy (KDT) is highly individualised and influenced by several patient-specific factors. The most common determinant was the clinical response to the diet, including seizure control and achievement of other therapeutic goals, cited by 91% of respondents. Seventy-five percent noted that the total duration on KDT influenced the weaning timeline, while 67% reported that patient or family preference played a role. Additional factors included any adverse effects experienced while on the diet (65%), level of ketosis achieved (55%), type of ketogenic diet used (43%), mode of feeding (33%), and the patient's age (with 16% taking longer to wean younger patients, although 5% reported the opposite). A smaller proportion (14%) also considered the epilepsy syndrome when planning discontinuation. For patients on CKDs, 40% of respondents reported weaning by reducing the ketogenic ratio by 0.5 at each step (e.g., 4:1 to 3.5:1 to 3:1), whereas 34% preferred to reduce the ratio by 1.0 per step. The remaining 26% used alternative or fully individualised protocols. For patients who had only been on the diet for a short time, weaning typically occurred over 1–4 weeks, while longer or more gradual reductions were reported for those on CKD for two years or more (Table 5). Example weaning protocols for both oral and enteral CKD are outlined in Tables S8 and S9.

Table 5. Length of time to wean off classical ketogenic diets: survey responses

Patients following CKD for at least 3 months	Agreement rate (% survey respondents)	Patients following CKD for at least 2 years	Agreement rate (% survey respondents)
1-2 weeks	33%	1-2 weeks	3%
3-4 weeks	25%	3-4 weeks	16%
Very individualized	27%	Very Individualized	45%
Less than 1 week	10%	1-2 months	22%
1 – 4 months	5%	4 – 6 months	5%

During the weaning process, over half of survey respondents (64%) continue to monitor ketone levels, while 23% do not. The remainder either leave the decision to families or monitor only until ketosis is no longer present. Regarding vitamin and mineral supplementation, 87% of respondents reported stopping supplementation at the end of the weaning process, whereas 5% only stopped once ketosis was lost. It is important to note that some form of supplementation may still be required for reasons unrelated to the ketogenic diet itself, such as concurrent medications or baseline nutritional status, and ongoing monitoring should be determined by local clinical practice, the healthcare system, and the responsibilities of the individual service or centre.

3.16.3. Dietary advice after discontinuing KDT

Following a successful period on KDT, some families may be hesitant to reintroduce carbohydrates (particularly processed or refined sources) due to concerns about seizure recurrence or other negative effects. This is an important consideration when supporting families in transitioning back to a more typical dietary pattern.

Survey findings reflect a wide range of professional approaches. One third of respondents recommend avoiding processed and refined sugars altogether when returning to a standard diet. Others take a more gradual approach: 21% advise slowly reintroducing simple carbohydrates, while 14% support gradual reintroduction of processed and refined sugars specifically. A smaller proportion (9%) advise avoiding simple carbohydrates entirely. Notably, 14% of respondents do not provide specific guidance on carbohydrate reintroduction, underscoring the variation in practice and the importance of tailoring advice to individual patient and family needs.

3.16.4. Follow-up post diet discontinuation

Post-diet discontinuation follow-up practices vary between services and are often influenced by local resources and patient needs. According to survey data, 34% of respondents discharge orally fed patients from their service once they are fully weaned off the KDT. Others continue to provide follow-up support for a period after discontinuation: 18% discharge patients more than four weeks after weaning is complete, 14% after two to four weeks, and 13% within one to two weeks. Decisions regarding continued follow-up are typically guided by individual clinical considerations, such as concerns about nutritional status or growth. In many cases, ongoing support may transition to general or community dietetic services, where available, to ensure continuity of care. This highlights the need for effective handover and clear communication between specialist ketogenic teams and broader healthcare services.

4. RESULTS: DIETETIC PRACTICE CORE RECOMMENDATIONS

Table 6 outlines the core recommendations for CKD, based on published evidence or survey consensus (≥75% agreement rate).

Table 6. Core recommendations for classical ketogenic diets

Aspect of dietary management	Source
Definition of classical ketogenic diet	
Any ketogenic diet that is based on a ratio of grams of fat to grams of protein and carbohydrate combined, usually in a ratio range of 2:1 to 4:1.	L1
Patient selection (dietary factors)	
CKD is preferred over MKDs in patients who are tube fed and for children aged under 2 years.	S
Pre-diet preparation	
Patients may benefit from pre-diet dietary adjustments before starting CKD, for example, by reducing simple sugars, trying out high-fat foods or ketogenic recipes.	S
- At least one education session is required, following agreement from the patient/family and the multidisciplinary healthcare team that KDT will be started. - At a minimum, education session should include the following topics: - Importance of adherence to the diet - Potential adverse effects - Follow up expectations - Identifying carbohydrates, protein, and fat sources - Weighing/measuring of foods and/or formula - Importance of hydration - Identify other sources of carbohydrate, such as medications - Supplements - Time commitment needed	S
Diet prescription (energy, fat, protein, carbohydrate, fluid)	
Energy requirements are based on standardized energy equations, current feeding regimen, and growth trends.	S; L1
Protein requirements should meet the dietary reference intake for age and weight, as a minimum and protein intake should be prioritized over carbohydrate. Sometimes, intakes below the dietary reference intake can be used in the short term.	S; L1
For modified texture diets, low-carbohydrate options, such as gum-based thickeners, may be used.	S
Fluid requirements should not be restricted.	S; L1
The ketogenic dietitian is typically responsible for advising on micronutrient supplementation, commonly a complete multivitamin and mineral supplement, plus additional supplements as required, such as carnitine (if low), calcium, and vitamin D.	S; L1
Enteral nutrition	
Nutritionally complete ketogenic enteral formulas should be used for those without allergies, including infants that are tube fed.	S; L1

Aspect of dietary management	Source
Prescribable ketogenic products	
• MCT oil and MCT-based products can be used as part of CKDs and the amount should be increased incrementally.	S
• For infants without allergies, an age-appropriate sole-source complete nutrition formula can be used.	S
• For infants with cow's milk protein allergy, modular components can be used.	S
Diet initiation	
• A gradual initiation without an initial fasting period helps reduce the risk of adverse effects and does not impact diet efficacy.	S; L1
• The KD ratio can be gradually increased, for example, from 1:1, to 2:1, to 3:1, depending on individual tolerance and response.	S; L1
• Glucose should be monitored when the diet is started as an inpatient.	S
• Glucose may be monitored initially when starting the diet as an outpatient.	S
• Ketones should be tested twice daily initially, and testing can be discontinued once ketones are stable.	S; L1
• Additional ketone testing is recommended in the event of signs of hyperketosis, illness or increase in seizures.	S; L1
Follow-up, monitoring and fine-tuning	
• Offer in-person clinic visits, or virtual clinic visits (where appropriate) at a minimum of 1, 3, 6 and 12 months post diet start, then 6-monthly.	L1
• Provide additional follow-up phone calls and/or emails as needed.	L1
• At follow-up appointments, anthropometrics, the nutritional adequacy of the diet prescription, diet adherence and any non-seizure benefits from KDT should be reviewed.	L1
• Adherence is measured by monitoring ketone levels and through discussions with patients/families.	S; L1
• Additional ketone checks may be done in the case of symptomatic hyperketosis, loss of seizure efficacy or during illness.	S
• The CKD should be fine-tuned based on individual seizure response and tolerance.	L1
• Consider adjusting the KD ratio, depending on diet efficacy, ketone levels, glucose levels, blood lipid profile and gastro-intestinal side effects.	S
• Consider use of MCT to promote higher levels of ketosis, if other changes to the diet prescription do not result in seizure improvement or if further restrictions in carbohydrate intake is not tolerated or possible.	S
• The diet prescription may be liberalized as patients get older, if needed.	S
Intercurrent illness	
• In case of constipation, increasing fluid intake and advise on fiber-rich food sources are considered.	S; L1
• For the treatment of acute hypoglycemia, a specified amount of a sugar-sweetened beverage, such as juice, or a specific amount of carbohydrate (grams) is recommended.	S
• In case of recurrent hypoglycemia, increasing carbohydrate intake in diet prescription is considered by dietitians is recommended.	S
• In case of illness, prioritize fluid intake, in some cases with an oral rehydration solution, and temporarily offer snack portions in place of full calorie meals.	S
• In case of hyperlipidemia, changing dietary fat sources is considered.	S; L1
• Meal replacements with ketogenic formula may be helpful in the interim.	L1

Aspect of dietary management	Source
Diet discontinuation	
There is no maximum amount of time that CKD can be followed but, if effective, diet discontinuation can be considered after approximately 2 years.	S; L2
If on diet for a short period of time (<3 months) with no/minimal response, CKD is most commonly weaned over 1-4 weeks.	S
If on diet for a longer period of time (>2 years) with good response, the length of time over which CKD is discontinued is most commonly individualized to each patient, but is generally longer than those on diet for short periods of time.	S
The KD ratio may be gradually reduced, for example, by 0.5 or 1 at each step; smaller steps may be used for individuals with good seizure control.	S; L1
Continue monitoring ketones whilst discontinuing CKD, but once ketone levels are minimal, the speed of transition back to the patient's usual diet can be increased.	S
Vitamin/mineral supplementation should be continued until the end of the diet discontinuation process.	S
Patients may be advised to avoid processed and refined sugars when they return to their usual diet, in line with general healthy eating guidelines, or to gradually re-introduce simple carbohydrates.	S
S = survey consensus (≥75% agreement); L1 = published consensus recommendations or international guidelines; L2 = published surveys, systematic reviews, meta-analyses, or randomised controlled trials	

5. DISCUSSION

These recommendations represent the first international best practice guidance for the dietetic management of children and young people with epilepsy following CKDs. They are grounded in a combination of published evidence and the most commonly reported dietetic practices, while also acknowledging and valuing the diversity of approaches used across different countries and healthcare systems.

The document is intended as a practical resource for ketogenic dietitians and nutrition professionals involved in the care of children and adolescents receiving medically advised CKDs for epilepsy management. While the recommendations seek to support greater consistency and quality in dietetic care worldwide, they are not prescriptive or mandatory, and clinical judgement remains essential. Local policy, patient preference, and resource availability should all be considered when applying these recommendations in practice.

Evidence to support dietetic management of KDT remains limited. The recommendations therefore reflect the best available evidence at the time of writing, alongside expert opinion and international survey data. As with all survey-based research, certain limitations must be acknowledged. These include the potential for sampling and response bias, and a relatively restricted set of response options. While we achieved a substantial number of respondents globally, the survey was designed to capture individual practice, which may not always represent centre-wide protocols. In cases where multiple dietitians from a single centre contributed, there is a possibility of overrepresentation of certain practices. However, this also reflects the reality that dietetic practice can vary between professionals even within the same institution.

6. CONCLUSION

Despite the limitations discussed, these recommendations are highly relevant to practicing dietitians and offer a valuable resource for supporting children and young people on CKDs. By promoting consistency in practice, they aim to enhance patient and family experience, support adherence to dietary therapy, and potentially improve clinical outcomes. Future research should prioritise the perspectives of service users and seek to evaluate the clinical impact of differing dietetic approaches, in order to further strengthen the evidence base and optimise care.

ABBREVIATIONS

The following abbreviations are used in this manuscript:

Term	Definition
BKD	Blended ketogenic diet
BMI	Body mass index
CKD	Classical ketogenic diet
IV	Intravenous
LGIT	Low glycemic index treatment
KDRN	Ketogenic Dietitians Research Network
KDT	Ketogenic diet therapy
MAD	Modified Atkins diet
MCT	Medium chain triglyceride
MKD	Modified ketogenic diet

REFERENCES

- ¹ Wilder RM. The Effect of Ketonemia on the Course of Epilepsy. *Mayo Clinic Bull* 1921(2):307-8.
- ² Schwartz RM, Boyes S, Aynsley-Green A. Metabolic effects of three ketogenic diets in the treatment of severe epilepsy. *Dev Med Child Neurol*. 1989;31(2):152-60.
- ³ RamachandranNair R, Stafstrom CE, Kossoff EH. Classic or classical ketogenic diet? Definitions and nomenclature. *Epileptic disorders : international epilepsy journal with videotape*. 2025.
- ⁴ Huttenlocher PR, Wilbourn AJ, Signore JM. Medium-chain triglycerides as a therapy for intractable childhood epilepsy. *Neurology*. 1971;21(11):1097-103.
- ⁵ Kossoff EH, Krauss GL, McGrogan JR, Freeman JM. Efficacy of the Atkins diet as therapy for intractable epilepsy. *Neurology*. 2003;61:1789-91.
- ⁶ Kossoff EH, McGrogan JR, Bluml RM, Pillas DJ, Rubenstein JE, Vining EP. A modified Atkins diet is effective for the treatment of intractable pediatric epilepsy. *Epilepsia*. 2006;47(2):421-4.
- ⁷ Martin-McGill KJ, Lambert B, Whiteley VJ, Wood S, Neal EG, Simpson ZR, Schoeler NE. Understanding the core principles of a 'modified ketogenic diet': a UK and Ireland perspective. *J Hum Nutr Diet*. 2019;32(3):385–90.
- ⁸ Pfeifer HH, Thiele EA. Low-glycemic-index treatment: a liberalized ketogenic diet for treatment of intractable epilepsy. *Neurology*. 2005;65(11):1810-2.
- ⁹ Kossoff EH, Zupec-Kania BA, Auvin S, Ballaban-Gil KR, Christina Bergqvist AG, Blackford R, et al. Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group. *Epilepsia Open*. 2018;3(2):175-92.
- ¹⁰ Whiteley VJ, Schoeler NE, Ketogenic Dietitians Research N. Nice to know 2: The impact of NICE guidelines on ketogenic diet services in the UK and Ireland - An update. *J Hum Nutr Diet*. 2024.
- ¹¹ Zilberter T, Zilberter Y. Ketogenic Ratio Determines Metabolic Effects of Macronutrients and Prevents Interpretive Bias. *Front Nutr*. 2018;5:75.
- ¹² National Institute for Health and Clinical Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care (update). 2012.
- ¹³ Cervenka MC, Wood S, Bagary M, Balabanov A, Bercovici E, Brown MG, et al. International Recommendations for the Management of Adults Treated With Ketogenic Diet Therapies. *Neurol Clin Pract*. 2021;11(5):385-97.
- ¹⁴ Armeno M, Caraballo R, Vaccarezza M, Alberti MJ, Rios V, Galicchio S, et al. [National consensus on the ketogenic diet]. *Revista de neurologia*. 2014;59(5):213-23.
- ¹⁵ Zupec-Kania B, Neal E, Schultz R, Roan ME, Turner Z, Welborn M. An update on diets in clinical practice. *J Child Neurol*. 2013;28(8):1015-26.
- ¹⁶ Lightstone L, Shinnar S, Callahan CM, O'Dell C, Moshe SL, Ballaban-Gil KR. Reasons for failure of the ketogenic diet. *J Neurosci Nurs*. 2001;33(6):292-5.

- ¹⁷ Poelzer K, Mannion C, Ortiz MM, Bang R, Woods P. A Systematic Review of the Quality of Life for Families Supporting a Child Consuming the Ketogenic Diet for Seizure Reduction. *Curr Dev Nutr*. 2019;3(5):nzz079.
- ¹⁸ Carroll JH, Martin-McGill KJ, Cross JH, Hickson M, Williams E, Aldridge V, Collinson A. Core outcome set development for childhood epilepsy treated with ketogenic diet therapy: Results of a scoping review and parent interviews. *Seizure*. 2022;99:54-67.
- ¹⁹ Sarlo GL, Holton KF. Caregiver perspectives on dietary therapies for epilepsy. *Epilepsy Res*. 2021;178:106803.
- ²⁰ Orr E, Whitney R, Nandeesh N, Kossoff EH, RamachandranNair R. Ketogenic Diet: Parental Experiences and Expectations. *J Child Neurol*. 2024;39(1-2):45-54.
- ²¹ Seo JH, Kim HD. Cultural challenges in using the ketogenic diet in Asian countries. 2008.
- ²² Kossoff E, Turner Z, Doerr S. Fine-tuning the diet. *The Ketogenic and Modified Atkins Diets: Treatments for Epilepsy and Other Disorders*. 6th ed. New York: Demos Health; 2016. p. 87.
- ²³ World Health Organisation. Human energy requirements. Report of a Joint FAO/WHO/UNU Expert Consultation. 2001.
- ²⁴ Nation J, Humphrey M, MacKay M, Boneh A. Linear growth of children on a ketogenic diet: does the protein-to-energy ratio matter? *J Child Neurol*. 2014;29(11):1496-501.
- ²⁵ Kossoff EH, Pyzik PL, Furth SL, Hladky HD, Freeman JM, Vining EP. Kidney stones, carbonic anhydrase inhibitors, and the ketogenic diet. 2002.
- ²⁶ Neal E. *Dietary Treatment of Epilepsy: Practical Implementation of Ketogenic Therapy*: Wiley-Blackwell; 2012.
- ²⁷ Ruiz Herrero J, Canedo Villarroja E, Garcia Penas JJ, Garcia Alcolea B, Gomez Fernandez B, Puerta Macfarland LA, Pedron-Giner C. Ketogenic dietary therapies for epilepsy: Experience in 160 patients over 18 years. *An Pediatr (Engl Ed)*. 2022;96(6):511-22.
- ²⁸ Bergqvist AG, Chee CM, Lutchka L, Rychik J, Stallings VA. Selenium deficiency associated with cardiomyopathy: a complication of the ketogenic diet. *Epilepsia*. 2003;44(4):618-20.
- ²⁹ Arslan N, Kose E, Guzel O. The effect of ketogenic diet on serum selenium levels in patients with intractable epilepsy. *Biol Trace Elem Res*. 2017;178(1):1-6.
- ³⁰ Kang HC, Chung DE, Kim DW, Kim HD. Early- and Late-onset Complications of the Ketogenic Diet for Intractable Epilepsy. *Epilepsia*. 2004;45:1116-23.
- ³¹ Willmott NS, Bryan RA. Case report: scurvy in an epileptic child on a ketogenic diet with oral complications. 2008.
- ³² Alten ED, Chaturvedi A, Cullimore M, Fallon AA, Habben L, Hughes I, et al. No longer a historical ailment: two cases of childhood scurvy with recommendations for bone health providers. *Osteoporos Int*. 2020;31(5):1001-5.
- ³³ Bank IM, Shemie SD, Rosenblatt B, Bernard C, Mackie AS. Sudden cardiac death in association with the ketogenic diet. *Pediatr Neurol*. 2008;39(6):429-31.
- ³⁴ Bergqvist AG, Schall JI, Stallings VA. Vitamin D status in children with intractable epilepsy, and impact of the ketogenic diet. *Epilepsia*. 2007;48(1):66-71.

- ³⁵ Kossoff EH, McGrogan JR, Freeman JM. Benefits of an all-liquid ketogenic diet. *Epilepsia*. 2004;45:1163.
- ³⁶ Hosain SA, La Vega-Talbott M, Solomon GE. Ketogenic diet in pediatric epilepsy patients with gastrostomy feeding. *Pediatr Neurol*. 2005;32(2):81-3.
- ³⁷ Batsis ID, Davis L, Prichett L, Wu L, Shores D, Au Yeung K, Oliva-Hemker M. Efficacy and Tolerance of Blended Diets in Children Receiving Gastrostomy Feeds. *Nutr Clin Pract*. 2020;35(2):282-8.
- ³⁸ Köglmeier J, Assecaira I, Banci E, De Koning B, Haiden N, Indrio F, et al. The Use of Blended Diets in Children With Enteral Feeding Tubes: A Joint Position Paper of the ESPGHAN Committees of Allied Health Professionals and Nutrition. *J Pediatr Gastr Nutr*. 2023;76(1):109-17.
- ³⁹ Diamanti A, Puntis J, Kolacek S, Hill S, Goulet O. Chapter 5.2.3. Parenteral Nutrition and Home Parenteral Nutrition Changed the Face of Paediatric Gastroenterology. *J Pediatr Gastroenterol Nutr*. 2018;66 Suppl 1:S82-S7.
- ⁴⁰ van der Louw E, Aldaz V, Harvey J, Roan M, van den Hurk D, Cross JH, et al. Optimal clinical management of children receiving ketogenic parenteral nutrition: a clinical practice guide. *Dev Med Child Neurol*. 2020;62(1):48-56.
- ⁴¹ Kossoff EH, Dorward JL, Turner Z, Pyzik PL. Prospective study of the modified atkins diet in combination with a ketogenic liquid supplement during the initial month. *Journal of child neurology*. 2011;26:147-51.
- ⁴² Miranda MJ, Turner Z, Magrath G. Alternative diets to the classical ketogenic diet--can we be more liberal? *Epilepsy Res*. 2012;100(3):278-85.
- ⁴³ Bergqvist AGC, Schall JI, Gallagher PR, Cnaan A, Stallings VA. Fasting versus gradual initiation of the ketogenic diet: a prospective, randomized clinical trial of efficacy. *Epilepsia*. 2005;46:1810-9.
- ⁴⁴ van der Louw E, van den Hurk D, Neal E, Leiendecker B, Fitzsimmon G, Dority L, et al. Ketogenic diet guidelines for infants with refractory epilepsy. *Eur J Paediatr Neurol*. 2016;20(6):798-809.
- ⁴⁵ Fabe J. Low ratio, Slow Outpatient Initiation & maintenance of Ketogenic Diet Therapy: Update and Practical Guidelines. 2020.
- ⁴⁶ Brooke J, Stiell M, Ojo O. Evaluation of the accuracy of capillary hydroxybutyrate measurement compared with other measurements in the diagnosis of diabetic ketoacidosis: a systematic review. *Int J Environ Res Public Health*. 2016;13(9).
- ⁴⁷ Gilbert DL, Pyzik PL, Freeman JM. The ketogenic diet: seizure control correlates better with serum beta-hydroxybutyrate than with urine ketones. *J Child Neurol*. 2000;15(12):787-90.
- ⁴⁸ van Delft R, Lambrechts D, Verschuure P, Hulsman J, Majoie M. Blood beta-hydroxybutyrate correlates better with seizure reduction due to ketogenic diet than do ketones in the urine. *Seizure*. 2010;19:36-9.
- ⁴⁹ Dressler A, Stocklin B, Reithofer E, Benninger F, Freilinger M, Hauser E, et al. Long-term outcome and tolerability of the ketogenic diet in drug-resistant childhood epilepsy - The Austrian experience. *Seizure*. 2010;19:404-8.
- ⁵⁰ Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N, Fitzsimmons G, et al. A randomized trial of classical and medium-chain triglyceride ketogenic diets in the treatment of childhood epilepsy. *Epilepsia*. 2009;50:1109-17.
- ⁵¹ Nordli DR, Jr., Kuroda MM, Carroll J, Koenigsberger DY, Hirsch LJ, Bruner HJ, et al. Experience with the ketogenic diet in infants. *Pediatrics*. 2001;108(1):129-33.

- ⁵² Cobo NH, Sankar R, Murata KK, Sewak SL, Kezele MA, Matsumoto JH. The ketogenic diet as broad-spectrum treatment for super-refractory pediatric status epilepticus: challenges in implementation in the pediatric and neonatal intensive care units. *J Child Neurol.* 2015;30(2):259-66.
- ⁵³ Thompson L, Fecske E, Salim M, Hall A. Use of the ketogenic diet in the neonatal intensive care unit-Safety and tolerability. *Epilepsia.* 2017;58(2):e36-e9.
- ⁵⁴ Wirrell E, Eckert S, Wong-Kissel L, Payne E, Nickels K. Ketogenic Diet Therapy in Infants: Efficacy and Tolerability. *Pediatr Neurol.* 2018;82:13-8.
- ⁵⁵ Fenton C, Groveman S, Chee CM, Bergqvist AGC. Benefits of a Ketogenic Teaching Kitchen. *Journal of Child Neurology.* 2019;34(14):886-90.
- ⁵⁶ Blackford R. Not your parents' ketogenic diet - Flexibility in 2020. *Epilepsy Res.* 2020;162:106307.
- ⁵⁷ Costa AM, Marchio M, Bruni G, Bernabei SM, Cavalieri S, Bondi M, Biagini G. Evaluation of E-Health Applications for Paediatric Patients with Refractory Epilepsy and Maintained on Ketogenic Diet. *Nutrients.* 2021;13(4).
- ⁵⁸ Boles S, Webster RJ, Parnel S, Murray J, Sell E, Pohl D. No improvement in quality of life in children with epilepsy treated with the low glycemic index diet. *Epilepsy & Behavior.* 2020;104.
- ⁵⁹ Cabrera AM, Fain H, Fain B, Muniategui J, Buiras VM, Galicchio S, et al. [Treatment of refractory epilepsy. A comparison between classic ketogenic diet and modified Atkins diet in terms of efficacy, adherence, and undesirable effects]. *Nutr Hosp.* 2021;38(6):1144-8.
- ⁶⁰ Armeno M, Caballero E, Verini A, Reyes G, Galarza N, Cresta A, Caraballo RH. Telemedicine-versus outpatient-based initiation and management of ketogenic diet therapy in children with drug-resistant epilepsy during the COVID-19 pandemic. *Seizure.* 2022;98:37-43.
- ⁶¹ Semprino M, Fasulo L, Fortini S, Martorell Molina CI, Gonzalez L, Ramos PA, et al. Telemedicine, drug-resistant epilepsy, and ketogenic dietary therapies: A patient survey of a pediatric remote-care program during the COVID-19 pandemic. *Epilepsy Behav.* 2020;112:107493.
- ⁶² Kossoff EH, Turner Z, Adams J, Bessone SK, Avallone J, McDonald TJW, et al. Ketogenic diet therapy provision in the COVID-19 pandemic: Dual-center experience and recommendations. *Epilepsy Behav.* 2020;111:107181.
- ⁶³ Selter JH, Turner Z, Doerrer SC, Kossoff EH. Dietary and medication adjustments to improve seizure control in patients treated with the ketogenic diet. *J Child Neurol.* 2015;30(1):53-7.
- ⁶⁴ Liu Y-MC. Medium-chain triglyceride (MCT) ketogenic therapy. *Epilepsia.* 2008;49 Suppl 8:33-6.
- ⁶⁵ Khoshoo V, Zembo M, King A, Dhar M, Reifen R, Pencharz P. Incidence of gastroesophageal reflux with whey- and casein-based formulas in infants and in children with severe neurological impairment. *J Pediatr Gastroenterol Nutr.* 1996;22(1):48-55.
- ⁶⁶ Cai QY, Zhou ZJ, Luo R, Gan J, Li SP, Mu DZ, Wan CM. Safety and tolerability of the ketogenic diet used for the treatment of refractory childhood epilepsy: a systematic review of published prospective studies. *World J Pediatr.* 2017;13(6):528-36.
- ⁶⁷ Chaffe H. Ketone monitoring and management of illness In: Neal E, editor. *Dietary Treatment of Epilepsy: Practical Implementation of Ketogenic Therapy*; Wiley Blackwell; 2012. p. 135-41.

- ⁶⁸ Valencia I, Pfeifer H, Thiele EA. General anesthesia and the ketogenic diet: clinical experience in nine patients. *Epilepsia*. 2002;43(5):525-9.
- ⁶⁹ Dressler A, Haiden N, Trimmel-Schwahofer P, Benninger F, Samueli S, Groppel G, et al. Ketogenic parenteral nutrition in 17 pediatric patients with epilepsy. *Epilepsia Open*. 2018;3(1):30-9.
- ⁷⁰ Kossoff EH, Nabbout R. Use of dietary therapy for status epilepticus. *J Child Neurol*. 2013;28(8):1049-51.
- ⁷¹ Groesbeck DK, Bluml RM, Kossoff EH. Long-term use of the ketogenic diet in the treatment of epilepsy. *Developmental Medicine and Child Neurology*. 2006;48(12):978-81.
- ⁷² Kossoff EH, Turner Z, Bergey GK. Home-guided use of the ketogenic diet in a patient for more than 20 years. *Pediatr Neurol*. 2007;36(6):424-5.
- ⁷³ Martinez CC, Pyzik PL, Kossoff EH. Discontinuing the ketogenic diet in seizure-free children: recurrence and risk factors. *Epilepsia*. 2007;48:187-90.
- ⁷⁴ Klepper J, Akman C, Armeno M, Auvin S, Cervenka M, Cross HJ, et al. Glut1 Deficiency Syndrome (Glut1DS): State of the art in 2020 and recommendations of the international Glut1DS study group. *Epilepsia Open*. 2020;5(3):354-65.
- ⁷⁵ Worden LT, Turner Z, Pyzik PL, Rubenstein JE, Kossoff EH. Is there an ideal way to discontinue the ketogenic diet? *Epil Res*. 2011;95:232-6.
- ⁷⁶ Kossoff EH, Rho JM. Ketogenic diets: evidence for short- and long-term efficacy. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics*. 2009;6:406-14.

SUPPLEMENTARY MATERIAL

Table S1. Search terms

Search topic	Search terms	Date of last search
Patient selection	(child* OR infant) AND (ketogenic OR "modified atkins") AND Epilepsy[MeSH Terms] AND (patient selection [MeSH Terms] OR Nutrition Assessment[MeSH Terms] OR contraindications[MeSH terms] OR "indication*")	14/02/2024
Patient selection (diet types)	(child* OR infant) AND (ketogenic OR "modified atkins") AND Epilepsy[MeSH Terms] AND (diet selection [MeSH Terms] OR Nutrition Assessment[MeSH Terms] OR contraindications[MeSH terms] OR "indication*")	22/02/2024
Diet prescription	(child* OR infant) AND (ketogenic OR "modified atkins") AND Epilepsy[MeSH Terms] AND ("diet prescription" OR "grams" OR "percentage energy" OR macronutrient* OR micronutrient* OR "ratio*")	12/02/2024
Mode of feeding	("child*" OR "infant") AND ("ketogenic" OR "modified atkins") AND Epilepsy[MeSH Terms] AND ("enteral" OR "tube" OR "blended" or "gastrostomy")	24/01/2024
Adolescents and ketogenic diets	(ketogenic OR "modified atkins") AND Epilepsy[MeSH Terms] AND (Infant[MeSH Terms] OR Child[MeSH Terms] OR Adolescent[MeSH Terms]) AND (social OR adapt*)	22/02/2024
Differences in practice with patients of different age group	(ketogenic OR "modified atkins") AND Epilepsy[MeSH Terms] AND (Infant[MeSH Terms] OR Child[MeSH Terms] OR Adolescent[MeSH Terms]) AND (Dietary Supplements[MeSH Terms] OR Infant Formula[MeSH Terms] OR prescrib*)	22/02/2024
Monitoring	(child* OR infant) AND (ketogenic OR "modified atkins") AND Epilepsy[MeSH Terms] AND ("monitoring" or "blood test" or "Monitoring, Ambulatory" or "lab*" or "blood work" or "adverse effects" [Subheading] or "side effects")	25/01/2024
Adherence	(child* OR infant) AND (ketogenic OR "modified atkins") AND Epilepsy[MeSH Terms] AND (psycho* OR social OR Treatment Adherence and Compliance[MeSH Terms] OR Patient Compliance[MeSH Terms])	13/02/2024
Telemedicine	(child* OR infant) AND (ketogenic OR "modified atkins") AND Epilepsy[MeSH Terms] AND (telemedicine* OR COVID-19 OR "virtual" OR "remote*" or "telehealth*")	25/01/2024

Table S2: List of commonly used ingredients and suggested alternatives for individuals with special dietary requirements

Ingredient	Substitute					
	Dairy	Egg	Soy	Peanuts	Tree Nuts	Wheat/Gluten
Oil	√	√	√			
Cream (Dairy)	Soy cream	√	Dairy cream	√	√	√
Egg	√	<u>Raising agents</u> Baking soda Baking powder “No egg” substitute <u>Protein Source</u> Pea protein Meat	√	√	√	√
Butter & Shortening	Olive oil butter Almond butter Coconut butter/ shortening Vegan butter, Avocado	Olive oil butter Almond butter Coconut butter/ shortening Vegan butter, Avocado	Dairy Butter Almond butter Vegan butter, Avocado	Olive oil butter Almond butter Coconut butter/ shortening Vegan butter, Avocado	Olive oil butter Vegan butter, Avocado	Olive oil butter Almond butter Coconut butter/ shortening Vegan butter, Avocado
Flour, Standard	Watch out for some Gluten free flour that contains dairy	Almond flour Soy Flour Walnut flour Standard flour	Almond flour Walnut flour Standard flour	Almond flour Soy Flour Gluten Free flour Walnut flour Standard flour	Standard flour Soy Flour Gluten Free flour	Almond flour Soy Flour Gluten Free flour Walnut flour
Generic Protein Powder	Pea protein	Skimmed milk powder Protifar™	Skimmed milk powder Protifar™	√	√	√
Generic Fat	Oil, dairy free butter/ margarine	Oil, butter, avocado	Oil, butter, avocado	Oil, butter, avocado	Oil, butter, avocado	Oil, butter, avocado
Formula / milk	Plant based keto products Rice milk Almond milk Soy milk	√	Rice milk Almond milk Dairy milk	√	√	√
Cheese	Soy cheese Vegan cheese	√	Dairy cheese	√	√	√
Almond Flour	√	√	√	√	√	√
Yoghurt	Soy yoghurt	√	Dairy yoghurt	√	√	√
Avocado	√	√	√	√	√	√
Berries	√	√	√	√	√	√
Cocoa Powder	√	√	√	√	√	√
Cream Cheese	Soy cream cheese	√	√	√	√	√

Table S3: Example classical ketogenic diet daily meal plan

3:1 ratio

9 year old child, Weight = 20 kg

Estimated dietary intake = 1339 kcal/day

3 meals and 2-3 snacks per day

Gram measurements are rounded to 1 decimal place

Meal Option #1 (Breakfast) - Wheat Biscuit Cereal with Yoghurt	Fat (g)	Protein (g)	Carbohydrate (g) excluding fibre
5g Wheat biscuits (cereal)	0.1	1.4	3.4
78g Unsweetened soya yoghurt	1.1	4.4	0.6
38g 50% fat emulsion (or 20g oil)	19	-	-
9g Blueberries, frozen	-	-	1
20g Extra thick double or heavy cream	10	0.3	0.2
Water	-	-	-
Total	30.1	5.3	5.2

Directions:

Mix yoghurt and fat emulsion together with the extra thick cream. Top with crumbled wheat biscuits & berries.

[Source of nutritional composition: New Zealand Food Composition Database (NZFCD). Values may vary between countries]

Meal Option #2 (Lunch) - Chickpea and Egg Curry	Fat (g)	Protein (g)	Carbohydrate (g) excluding fibre
90g Oil	89.9	-	-
85g Mushrooms, raw, chopped	0.2	2.0	0.8
50g Spinach, raw	0.2	1.3	0
20g Spring onion, raw, chopped	0.1	0.2	1.8
10g Tomato puree	0	0.3	2.0
10g Curry powder	1.1	0.9	3.7
5g Garlic, puree or minced	0	0.4	0.4
80g Tinned chopped tomatoes	0.1	1.0	2.6
52g Chickpeas, tinned, drained, no added salt	0.8	3.6	7.7
80g Egg, cooked, chopped	6.5	10.5	0.7
42g 50% fat emulsion	21	-	-
Total for 4 servings (batch)	120	20	20
Total for each serving	30	5	5

Directions:

Heat oil in a pan and add mushrooms. Allow the mushrooms to soak up the fat.

Add spinach, spring onion, tomato puree, curry paste and garlic puree.

Add chopped tomatoes and chickpeas and cook on low heat for 5 mins.

Let it simmer until the curry is slightly reduced.

Once vegetables are cooked, take off the heat and stir in the chopped egg and fat emulsion.

[Source of nutritional composition: New Zealand Food Composition Database (NZFCD). Values may vary between countries]

Meal Option #3 (Lunch) - Stir Fry Konjac Noodles with Fried Egg and Capsicum	Fat (g)	Protein (g)	Carbohydrate (g) excluding fibre
3g Sesame seeds	1.5	0.5	0.4
125g Konjac noodles	1	1	1
36g Pepper, capsicum, yellow, raw or ¼ or ⅓ capsicum, chopped	0.1	0.3	1.7
36g Pepper, capsicum, red, raw or ¼ capsicum, chopped	0.1	0.3	1.6
21g Egg, whole, raw	1.7	2.8	0.2
21g Vegetable Oil	20.7	0	0.2
5g Sesame Oil	5	0	0
Total	30	5	5

Directions:

Drain the konjac noodles.

Beat the raw egg. Heat the pan with 5g vegetable oil. Fry the egg. Cut the fried egg into strips.

Use the same pan, heat the remaining 15g vegetable oil. Add onion and fry until golden and fragrant.

Add peppers, drained konjac noodles and soy sauce and stir fry.

Finally, add the egg strips. Cook and stir fry for a couple more minutes.

Top with sesame seeds and sesame oil.

[Source of nutritional composition: McCance and Widdowson's 'The Composition of Foods seventh summary edition.' CoFID 2015]

Meal Option #4 (Dinner/Supper) - Baked Cod with Mixed Vegetable 'Couscous'	Fat (g)	Protein (g)	Carbohydrate (g) excluding fibre
10g Cod, baked	0.1	2.1	0
25g Butter	20.9	0.1	0.2
5g Lime juice	0	0	0.1
4g Garlic puree	0	0.3	0.4
50g Cauliflower, grated, cooked	0.2	1.1	1.4
6.5g Olive oil	6.5	0	0
30g Cherry tomatoes, chopped	0.1	0.2	0.9
13g Green olives, pitted and chopped	2	0.1	0
45g Courgette, chopped	0.1	0.8	0.7
30g Red pepper, chopped	0.1	0.3	1.3
1g Capers	0	0	0
Total	30	5	5

Directions:

In a small bowl, whisk together lime juice, melted butter, stir in the garlic and capers and season.

Steam or microwave the grated cauliflower and set aside.

Fry the chopped tomatoes, courgette and red pepper in olive oil. Once soft, combine with the cauliflower and green olives and add the butter mixture.

Serve with the baked cod.

[Source of nutritional composition: McCance and Widdowson's 'The Composition of Foods seventh summary edition.' CoFID 2015]

Snack Option #1 (Afternoon Tea) - Chocolate Chip Cookie	Fat (g)	Protein (g)	Carbohydrate (g) excluding fibre
24g Butter	19.5	0.2	0.2
75g Double or heavy cream (50% fat)	36	1.3	1.9
70g Ground almonds/almond meal	35.4	15.3	8.5
15g Sugar free chocolate chips	4.4	1	3.6
40g Unsweetened desiccated coconut	24.8	2.2	5.5
20g Stevia sweetener	-	-	-
Total for 8 servings (batch)	120	20	20
Total for each serving	15	2.5	2.5

Directions:

- 1) Preheat oven to 150 °C (300 °F).
- 2) Lightly grease a biscuit tray with oil spray.
- 3) Beat butter and sweetener together until pale and fluffy.
- 4) Mix all other ingredients together.
- 5) Using heaped teaspoon quantities, shape mixture into balls. If these do not form easily, add a little water to help combine them.
- 6) Place balls onto tray and flatten slightly with a fork.
- 7) Place in oven and bake for 20 - 25 mins.

[Source of nutritional composition: McCance and Widdowson's 'The Composition of Foods seventh summary edition.' CoFID 2015]

Snack Option #2 (Afternoon Tea) - Chocolate Drink / Hot Chocol	Fat (g)	Protein (g)	Carbohydrate (g) excluding fibre
10g Sugar free chocolate drinking powder	0.1	0.2	0.8
26g Double or heavy cream (50% Fat)	12.5	0.4	0.7
133g Unsweetened almond milk	1.6	0.8	0.4
2.6g Sugar-free dark chocolate bits	0.8	0.2	0.6
1g Protein modular	0	0.9	0
Total	15	2.5	2.5

Directions:

Put almond milk and cream in a small saucepan and cook over medium heat.

While the milk is heating, place the chopped chocolate in the microwave and heat for 30 seconds at half the power setting. Take the chocolate out and stir it. Return to the microwave and heat for another 30 seconds. Remove and stir. Continue to heat and stir the chocolate in 30 second intervals until melted, then stir in the chocolate drinking powder. When the milk reaches the scalding point (bubbling around the edges), turn off the heat and whisk in the melted chocolate mixture.

[Source of nutritional composition: New Zealand Food Composition Database (NZFCD) FOODFiles 2014. Values may vary between countries]

Snack Option #3 (Afternoon Tea) - Vegetables and Cheese with Mayonnaise Platter	Fat (g)	Protein (g)	Carbohydrate (g) excluding fibre
5g Cheddar Cheese	1.7	1.2	0.2
25g Cucumber with peel, raw	0	0.2	0.4
15g Mayonnaise, Japanese style	11.5	0.2	0.2
15g Olives, in brine	1.6	0.1	0.4
15g Peas, frozen	0.1	0.8	1.4
Total	15	2.5	2.5

Directions:

Cut up ingredients into bite-size pieces. Arrange nicely like charcuterie board.

[Source of nutritional composition: New Zealand Food Composition Database (NZFCD) FOODFiles 2014. Values may vary between countries]

Meal Option #5 - Blended Meal for Oral or Tube Feeding	Fat (g)	Protein (g)	Carbohydrate (g) excluding fibre
Dairy Free, Gluten Free, Soya Free, Egg Free, and Peanut Free			
200g Lamb mince, raw	40	33	-
175g Potato, raw, chopped	0.1	3	34
150g Olive oil	150	-	-
30g Peas, frozen	0.2	1.5	3.2
50g Spinach, raw, chopped	0.1	1	0.8
50g Broccoli, raw, chopped	0.1	2	1.5
100g 50% fat emulsion	50	-	-
Total for 8 servings (batch)	240.5	40.5	39.5
Total for each serving	30	5	4.9

Directions:

Weigh and prepare all ingredients.

Heat 15g of olive oil in a pan and fry lamb mince until brown, then add the vegetables and some water.

Simmer for 10-15 mins (add more water if the mixture dries up quickly) until soft.

Turn off heat and allow to cool. Blend in the rest of the olive oil and emulsion.

Add water to get the desired consistency.

[Source of nutritional composition: McCance and Widdowson's 'The Composition of Foods seventh summary edition.' CoFID 2015]

Table S4: List of ketogenic prescribable products

Product	Company	Description	Indications*
Nutritionally complete			
Ketocal 4:1 powder	Nutricia	Powdered feed enriched with multi-fibre and LCPs available in vanilla and unflavoured varieties. The standard feed concentration is 14.3%	Suitable as a sole source of nutrition, in children aged 1-10 years or as a supplement for those over 10 years and adults.
Ketocal 4:1 LQ	Nutricia	Ready to use fibre enriched liquid feed available in vanilla and unflavoured varieties	Suitable as a sole source of nutrition in children aged 1–10 years or as a supplement for those over 10 years and adults
Ketocal 3:1 powder	Nutricia	Powdered feed, fibre-free, enriched with LCPs, unflavoured. The standard feed concentration is 9.5%	Suitable as a sole source of nutrition in infants from birth to 3 years or as a supplement in those over 3 years (UK version).
Ketocal 2.5:1 LQ	Nutricia	Ready to use multi-fibre enriched liquid feed with 21% of total energy from MCT. Available in vanilla flavour	Suitable as a sole source of nutrition in children aged 8 years to adults or as a supplement
Ketovie 4:1	Cortex Health / Ajinomoto Cambrooke Inc	Ready to use fibre, carnitine and citrate enriched liquid feed with 25% of total energy from MCT. Available in unflavoured, vanilla or chocolate flavour	Suitable as a sole source of nutrition in children from 1 year of age
Ketovie Peptide 4:1	Cortex Health / Ajinomoto Cambrooke Inc	Extensively hydrolyzed whey protein. Ready to use fibre, carnitine and citrate enriched liquid feed with 15% of total energy from MCT	Suitable as a sole source of nutrition in children from 1 year of age
Ketovie 4:1 Plant-Based Protein	Cortex Health / Ajinomoto Cambrooke Inc	Pea protein Ready to use fibre, carnitine and citrate enriched liquid feed with 25% of total energy from MCT	Milk and soy allergies. Suitable as a sole source of nutrition in children from 1 year of age
Ketovie 3:1	Cortex Health / Ajinomoto Cambrooke Inc	Ready to use partially hydrolyzed whey protein with 20% of total energy from MCT. Enriched with prebiotic fibre and carnitine	Suitable as a sole source of nutrition in children from 1 year of age
K.Flo 4:1	Nestle Health Science/VitaFlo	Ready to use fibre-enriched liquid feed available in vanilla	Suitable from 3 years of age onwards
Ketonia	Namyang Dairy Products Co., Ltd.	Ready to use liquid formula for oral or enteral use in infants and young children	Suitable from birth
K.Yo	Nestle Health Science/VitaFlo	Ready to eat semi-solid food	Suitable from 3 years of age onwards. Suitable as a sole source of nutrition up to 10 years of age
Ketobiota 2.5:1	Dr Schaer/Kanso	Powdered, texture can be adapted (e.g. liquid or yogurt) with 73% of total energy from MCT. Enriched with 11 vitamins	Suitable from 3 years of age onwards

Product	Company	Description	Indications*
KetoEpi 2:1	Dr Schaer/Kanso	Ready to use liquid formula with 65% of total energy from MCT, allergen-free	Suitable from 3 years of age onwards Suitable as a sole source of nutrition
KetVit	Dr Schaer/Kanso	Ready to eat creamy food, with 44% MCT. Enriched with minerals, vitamins and fiber Ketogenic ratio 5.7:1	Suitable from 3 years of age
MCTfiber	Dr Schaer/Kanso	Powder, 60% MCT and ketogenic ratio 7.2:1. Added with soluble fiber	Suitable from 3 years of age
DeliMCT creams (champignons, tomatoes, classical)	Dr Schaer/Kanso	Ready to use, enriched with MCT (ranging from 85% to 95% of total energy)	Suitable from 3 years of age
MCT Margarine 83%	Dr Schaer/Kanso	Ready to eat, with 83% MCT fat of the total fat content. Enriched with omega-3 + omega-6, vitamins A, D, E, folate, vitamin B12	Suitable from 1 years of age Maximum temperature 180°
DeliMCT Cacaobar	Dr Schaer/Kanso	Ready to eat, with 33% of total energy from MCT, enriched in fiber. Ketogenic ratio 5.2:1	Suitable from 3 years of age
KetoClassic 3:1 Bisk	Ketocare foods	3:1 ratio high fat, high fibre food	Suitable from 3 years of age
KetoClassic 3:1 breakfast Porridge	Ketocare foods	3:1 ratio, high fat, high fibre, ready prepared meal	Suitable from 3 years of age
KetoClassic 3:1 breakfast Muesli	Ketocare foods	3:1 ratio, high fat, high fibre, ready prepared meal	Suitable from 3 years of age
KetoClassic 3:1 meal Savoury	Ketocare foods	3:1 ratio, high fat, high fibre solid meal	Suitable from 3 years of age
KetoClassic 3:1 meal Chicken	Ketocare foods	3:1 ratio, high fat, ready prepared meal	Suitable from 3 years of age
KetoClassic 3:1 meal Bolognese	Ketocare foods	3:1 ratio, high fat, ready prepared meal	Suitable from 3 years of age
Carbohydrate free formula			
RCF	Abbott	Liquid feed very low in carbohydrate, soy protein	Milk allergy Suitable from birth
Carb free mix	Nutricia	Powdered feed very low in carbohydrate	Suitable for infants and children
Fat modules			
Liquigen	Nutricia	Ready to use 50% MCT emulsion	Suitable for children and adults
MCT oil	Nutricia	Liquid containing only a mixture of MCT	Suitable for children and adults
MCT oil (77% and 100%)	Dr Schaer/Kanso	Liquid containing only a mixture of MCT	Suitable from birth
MCT 100% must be used raw			
Calogen	Nutricia	50% LCT fat emulsion	Use with caution in children under 6 years of age
K.Quik	Nestle Health Science/Vitafo	Ready to use 20% emulsion of MCT	Suitable from 3 years of age

Product	Company	Description	Indications*
Protein modules			
Protifar	Nutricia	Powdered milk based high protein supplement	Not suitable for children under 3 years of age
Complete Amino Acid Mix	Nutricia	Powdered mix of essential and non-essential amino acids	Suitable from birth
Beneprotein	Nestle Health Science	Powdered milk based high protein supplement	Suitable from birth
MCT Procal	Nestle Health Science/Vitaflo	Neutral tasting protein powder supplement high in MCT	Suitable from 3 years of age
ProSource TF	Nutrinovo	Liquid high protein milk-free (beef collagen derivative) supplement for tube feeding	Suitable from 3 years of age
Carbohydrate modules			
Polycal/Polyjoule	Nutricia	Powdered unflavoured carbohydrate supplement	Suitable from 1 year of age
Super Soluble Maxijul	Nutricia	Powdered neutral flavoured carbohydrate energy source	Suitable from birth
Vitajoule	Nestle Health Science/Vitaflo	Powdered unflavoured carbohydrate supplement	Suitable from birth
Other			
Keto Peptide	Functional Formularies	Whole foods-based formula (2.43:1 ratio). Includes peptide proteins.	No specific indications given

LCP, long chain polyunsaturated fatty acids; MCT, medium chain triglycerides; LCT, long chain triglycerides

*Indications may vary between countries

Table S5: Example initiation schedules for an oral classical 3:1 ketogenic diet

Patient details: 9 year old child, 'Jamie.' Appropriate growth history.

Target CKD prescription 3:1 ratio

Macronutrients: 1340 kcal, 20g protein, 130g fats and 23g carbohydrates

Initiation over 2 weeks	Ratio increments in steps of 0.5	Ratio increments in steps of 1
Day 1	1:1 (103g fat, 20g protein, 83g carbohydrate)	1:1 (103g fat, 20g protein, 83g carbohydrate)
Day 2		
Day 3		
Day 4	1.5:1 (115g fat, 20g protein, 56.5g carbohydrate)	
Day 5		
Day 6		
Day 7	2:1 (122g fat, 20g protein, 41g carbohydrate)	2:1 (122g fat, 20g protein, 41g carbohydrate)
Day 8		
Day 9		
Day 10	2.5:1 (126g fat, 20g protein, 30g carbohydrate)	
Day 11		
Day 12		
Day 13	3:1 (130g fat, 20g protein, 23g carbohydrate)	
Day 14		3:1 (130g fat, 20g protein, 23g carbohydrate)

Initiation over 3 weeks	Ratio increments in steps of 0.5	Ratio increments in steps of 1
Day 1	1:1 (103g fat, 20g protein, 83g carbohydrate)	1:1 (103g fat, 20g protein, 83g carbohydrate)
Day 3	1.5:1 (115g fat, 20g protein, 56.5g carbohydrate)	
Day 8	2:1 (122g fat, 20g protein, 41g carbohydrate)	2:1 (122g fat, 20g protein, 41g carbohydrate)
Day 11	2.5:1 (126g fat, 20g protein, 30g carbohydrate)	
Day 15	3:1 (130g fat, 20g protein, 23g carbohydrate)	3:1 (130g fat, 20g protein, 23g carbohydrate)

Initiation over 6 weeks	Ratio increments in steps of 0.5	Ratio increments in steps of 1
Week 1	0.5:1 (79g fat, 20g protein, 138g carbohydrate)	1:1 (103g fat, 20g protein, 83g carbohydrate)
Week 2	1:1 (103g fat, 20g protein, 83g carbohydrate)	
Week 3	1.5:1 1.5:1 (115g fat, 20g protein, 56.5g carbohydrate)	2:1 (122g fat, 20g protein, 41g carbohydrate)
Week 4	2:1 (122g fat, 20g protein, 41g carbohydrate)	
Week 5	2.5:1 (126g fat, 20g protein, 30g carbohydrate)	
Week 6	3:1 (130g fat, 20g protein, 23g carbohydrate)	3:1 (130g fat, 20g protein, 23g carbohydrate)

Table S6: Example 3-week initiation schedule for an enteral classical 3:1 ketogenic diet

Patient details: 9 year old child, 'Jamie.' Appropriate growth history.

Target CKD prescription 3:1 ratio

Macronutrients: 1340kcal, 20g protein, 130g fat and 23g carbohydrate

5 feeds per day of 200ml each

Each feed to contain: 268 kcal, 4g of protein, 26g of fat, 4.6g of carbohydrate

Week 1	Fat (g)	Protein (g)	Carbohydrate (g)
1:1 classical ratio (each feed: 20.6g fat, 4g protein, 16.6g carbohydrate)			
16g carbohydrate polymer	-	-	15.4
70ml water	-	-	-
130ml 4:1 liquid keto formula (1.5kcal/ml)	19.2	4	0.8
2ml 50% fat emulsion	1	-	-
Total	20.2	4	16.2
Mix the powder with the water then add liquid supplements			

Week 2	Fat (g)	Protein (g)	Carbohydrate (g)
2:1 classical ratio (each feed: 24.4g fat, 4g protein, 8.2g carbohydrate)			
8g carbohydrate polymer	-	-	7.7
60ml water	-	-	-
130ml 4:1 liquid keto formula (1.5kcal/ml)	19.2	4	0.8
10ml 50% fat emulsion	5	-	-
Total	24.2	4	8.5
Mix the powder with the water then add liquid supplements			

Week 3	Fat (g)	Protein (g)	Carbohydrate (g)
3:1 classical ratio (each feed: 26g fat, 4g protein, 4.6g carbohydrate)			
4g carbohydrate polymer	-	-	3.8
50ml water	-	-	-
130ml 4:1 liquid keto formula (1.5kcal/ml)	19.2	4	0.8
14ml 50% fat emulsion	7	-	-
Total	26.2	4	4.6
Mix the powder with the water then add liquid supplements			

Table S7: Advantages and disadvantages of the use of telemedicine for ketogenic diet therapy

Advantages	Disadvantages
Reduces travel time, so particularly beneficial for patients/families who have to travel long distances, potentially with nursing needs such as suction difficulties or mechanical ventilation, and/or behavioral disorders or mobility issues ¹ Environmental benefit of reducing travel ²	May not be appropriate for young infants, clinically unstable patients, those at high risk of hypoglycemia or metabolic issues, families without access to technology, and those unable to access emergency medical care if necessary ³
Can reduce waiting lists ¹	Inconsistency with anthropometric measurements and difficulties in getting clinical information/results (labs and other routine assessments) ^{1,3}
May reduce patient / family stress ²	Detailed discussions may seem less personal when done by video call - particularly pertinent when discussing diet discontinuation, or lack of response to treatment ^{1,3}
Multiple family members and caregivers may be able to join the education sessions ³	Technological aspects, such as difficulties with connecting online, can be a limiting factor ¹
Allows the team to see the patient in their own house (potentially including the kitchen) ²	
Electronic communication may be appealing for adolescents ⁴	

References:

- ¹ Armeno M, Caballero E, Verini A, *et al.* Telemedicine- versus outpatient-based initiation and management of ketogenic diet therapy in children with drug-resistant epilepsy during the COVID-19 pandemic. *Seizure*. 2022, **98** 37-43.
- ² Bara VB, Schoeler N, Carroll JH, *et al.* Patient and carer perspectives on the use of video consultations in the management of the ketogenic diet for epilepsy. *Epilepsy Behav*. 2023, **145** 109280.
- ³ Kossoff EH, Turner Z, Adams J, *et al.* Ketogenic diet therapy provision in the COVID-19 pandemic: Dual-center experience and recommendations. *Epilepsy Behav*. 2020, **111** 107181.
- ⁴ Cervenka MC, Henry BJ, Felton EA, *et al.* Establishing an Adult Epilepsy Diet Center: Experience, efficacy and challenges. *Epilepsy Behav*. 2016, **58** 61-8.

Table S8: Worked examples of how to discontinue a classical ketogenic diet

Patient details: 9-year-old child, 'Jamie.' Appropriate growth history. 3 meals and 3 snacks per day for an oral CKD or 6 equal feeds for enteral CKD

Short time on the diet (less than 3 months) and/or need to rapidly wean off the diet

Full CKD prescription **3:1 ratio**

1340,00 kcal, 20 g proteins, 129.7 g fats and 23.2 g carbohydrates

3 meals and 3 snacks a day

One-week discontinuation protocol with one CKD ratio decrease every 2-3 days*

Days 1-3	2:1 ratio 1340 kcal, 20 g protein, 121.8 g fats and 40.9 g carbohydrates
Days 4-6	1:1 ratio 1340 kcal, 20 g protein, 103.1 g fats and 83.1 g carbohydrates
Day 7	Liberal/usual diet

One-week discontinuation protocol with a 0.5 CKD ratio decrease every 2 days

Day 1-2	2.5:1 ratio 1340 kcal, 20 g protein, 126.5 g fats and 30.6g carbohydrates
Day 3-4	2:1 ratio 1340 kcal, 20 g protein, 121.8 g fats and 40.9 g carbohydrates
Day 5-6	1.5:1 ratio 1340 kcal, 20 g protein, 115 g fats and 56.5 g carbohydrates
Day 7	1:1 ratio 1340 kcal, 20 g protein, 103.1 g fats and 83.1 g carbohydrates
Day 8	Liberal/usual diet

Six-weeks discontinuation protocol with one CKD ratio decrease every 2 weeks

Weeks 1-2	2:1 ratio 1340 kcal, 20 g protein, 121.8 g fats and 40.9 g carbohydrates
Weeks 3-4	1:1 ratio 1340 kcal, 20 g protein, 103.1 g fats and 83.1 g carbohydrates
Week 5	Liberal/usual diet

Four-weeks discontinuation protocol with a 0.5 CKD ratio decrease every week**

Week 1	2.5:1 ratio 1340 kcal, 20 g protein, 126.5 g fats and 30.6g carbohydrates
Week 2	2:1 ratio 1340 kcal, 20 g protein, 121.8 g fats and 40.9 g carbohydrates
Week 3	1.5:1 ratio 1340 kcal, 20 g protein, 115 g fats and 56.5 g carbohydrates
Week 4	1:1 ratio 1340 kcal, 20 g protein, 103.1 g fats and 83.1 g carbohydrates
Week 5	Liberal/usual diet

* If the initial prescription ratio is 4:1, you can decrease by one CKD ratio every 2 days

** If the initial prescription is 4:1 CKD ratio, the same can be done in 4 weeks with a one CKD ratio decrease each 7 days

Table S9: Worked examples of how to discontinue an enteral classical ketogenic diet

Patient details: 9 year old child, 'Jamie.' Appropriate growth history.

3:1 ratio

6 feeds per day

3:1 ratio

1340 kcal, 20 g protein, 129.7 g fats and 23.2g carbohydrates

Target content for each feed: 233 kcal, 3.3 g of protein, 21.6 g of fats, 3.9 g of carbohydrates

	Protein (g)	Fat (g)	Carbohydrate (g)
107ml 4:1 ketogenic formula	3.3	15.8	0.7
3.2g Carbohydrate module	0	0	3
11.6ml 50% fat emulsion module	0	5.8	–
Total	3.3	21.6	3.9

Step 1 - week 1

2:1 ratio

1340 kcal, 20 g protein, 121.8 g fats and 40.9 g carbohydrates

Target content for each feed: 233 kcal, 3.3 g of protein, 20.3 g of fats, 6.8 g of carbohydrates

	Protein (g)	Fat (g)	Carbohydrate (g)
80ml 4:1 ketogenic formula	2.5	11.8	0.5
55ml 1kcal/ml enteral formula	1.5	2.7	6.3
13ml 50% fat emulsion module	0	6.5	–
Total	4	21	6.8

Step 2 - week 2

1:1 ratio

Daily total 1340kcal, 20 g protein, 103.1 g fats and 83.1 g carbohydrates

Target content for each feed: 233 kcal, 3.3 g of protein, 17.2 g of fats, 13.9 g of carbohydrates

	Protein (g)	Fat (g)	Carbohydrate (g)
30ml 4:1 ketogenic formula	0.6	2.8	0.1
110ml 1kcal/ml enteral formula	2.8	4.4	13.8
20ml 50% fat emulsion module	0	10	–
Total	3.3	17.2	13.9

Then transition to normal enteral formula

Example classical ketogenic diet recipes using KetoCal provided by Nutricia

2:1 Chicken curry

Recipe serves: 1

	Fat (g)	Protein (g)	Carbohydrate (g) excluding fibre
10 g KetoCal 4:1 Powder (unflavoured)	6.9	1.4	0.3
11 g olive oil	11.0	–	–
15 g chicken breast	0.2	4.6	–
15 g mushrooms	–	0.2	–
8 g green pepper	–	0.1	0.2
8 g spring onions, white part only	–	0.1	0.7
3 g tomato puree	–	0.1	0.4
3 g garlic puree	1.0	0.1	0.5
20 g tinned tomatoes	–	0.2	0.8
2 g curry powder	0.2	0.2	0.5
10 g water	–	–	–
Total entire recipe	19.5	7.0	3.4

Directions:

Place oil in saucepan and heat, add chicken, mushroom, pepper, tomato puree, spring onion and garlic puree and cook on medium heat for 10 mins.

Add chopped tomatoes, curry powder and water, cook for further 10 mins on low heat.

Mix KetoCal 4:1 Powder into the curry (do not boil) and serve immediately.

3:1 Yogurt breakfast

Recipe serves: 1

	Fat (g)	Protein (g)	Carbohydrate (g) excluding fibre
15 g KetoCal 4:1 Powder (unflavoured or vanilla)	10.4	2.2	0.4
60 ml Alpro Soya Yogurt - plain	1.4	2.4	–
18 g raspberries, frozen	0.1	0.2	0.9
11 g olive oil	10.0	–	–
Total entire recipe	11.4	2.6	0.9

Directions:

Place the frozen raspberries in a bowl with the olive oil and mash with a fork until you have a puree, (add sweetener at this stage if needed).

Mix the yogurt and KetoCal 4:1 powder, then stir through the raspberry puree.

Serve or place in the fridge until needed.

IMPORTANT NOTICE: KetoCal is a food for special medical purposes for ketogenic dietary therapy management of epilepsy and Glut1 deficiency syndrome and must be used under medical supervision. KetoCal intake is to be determined by a medical professional and is dependent on the age, weight, energy needs of the individual.

PLEASE NOTE: Nutritional analysis is based on recipes from MyKetoPlanner. Please check individual food labels for exact composition.

3:1 Vanilla biscuits

	Fat (g)	Protein (g)	Carbohydrate (g) excluding fibre
5 g KetoCal 4:1 Powder (vanilla)	3.5	0.7	0.1
7 g butter. unsalted	5.8	–	–
20 g almonds. flaked and ground	11.2	4.2	1.5
5 g low carbohydrate icing sweetener	–	–	–
Total entire recipe	20.4	5.0	1.7

Directions:

Use room temperature soft butter for this recipe.

Cream the butter and icing sweetener with a few drops of vanilla extract, (you can use almond extract, orange zest, lemon zest, pinch of ground cinnamon, or ground ginger).

Add the ground almonds and KetoCal 4:1 Powder, and mix until you have a soft dough, chill in the fridge for 30 minutes

Line a cookie sheet or baking tray with baking paper.

Cut the dough into 4 and roll into a smooth ball, place on the cookie sheet, and press down slightly, (you can make bigger or smaller biscuits as needed).

Bake at 170°C for 8/10 minutes until the top is a golden brown if you make it bigger or smaller biscuits adjust the timing to suit.

Cool on the tray then store in a biscuit tin or airtight container.

Biscuits can be shaped and frozen until needed, when baking add a few minutes to the cooking times.

4:1 Savoury crackers

Recipe serves: 4

	Fat (g)	Protein (g)	Carbohydrate (g) excluding fibre
14 g KetoCal 4:1 Powder (unflavoured)	9.7	2.0	0.4
5 g water	–	–	–
7 g olive oil	6.4	–	–
10 ml egg white. beaten	–	1.1	0.1
3 g full fat Cheddar cheese	1.1	0.8	–
Total entire recipe	17.1	3.9	0.5

Directions:

Preheat oven to 170°C/gas mark 5.

Mix KetoCal 4:1 Powder with water and oil to form a batter.

Whisk egg whites into batter mix.

Divide into 4 and place on baking parchment.

Use a spatula to shape each into a 2" circle and sprinkle cheese on top.

Cook on one side for 10 mins or until golden brown, turn over and cook for a further 5 mins until crisp.

Once cooked, remove and place on a wire tray before eating.

IMPORTANT NOTICE: KetoCal is a food for special medical purposes for ketogenic dietary therapy management of epilepsy and Glut1 deficiency syndrome and must be used under medical supervision. KetoCal intake is to be determined by a medical professional and is dependent on the age, weight, energy needs of the individual.

PLEASE NOTE: Nutritional analysis is based on recipes from MyKetoPlanner. Please check individual food labels for exact composition.

4:1 Courgette muffins

	Fat (g)	Protein (g)	Carbohydrate (g) excluding fibre
20 g KetoCal 4:1 Powder (unflavoured)	13.8	2.9	0.6
40 g courgette	0.2	0.7	0.7
16 g whipping cream	6.5	0.3	0.4
10 g butter, unsalted	8.2	0.1	0.1
20 g egg	1.8	2.5	–
10 ml canola oil	10.0	–	–
10 g Cheddar cheese	3.5	2.5	–
Total entire recipe	44.0	9.0	1.8

Directions:

Heat oven to 170°C (350 F).

Grate the courgettes finely.

Mix all ingredients together. Add salt/pepper according to taste.

Pour into silicone muffin cases.

Bake for approx. 15 minutes until golden brown.

4.1 Chicken nuggets

Recipe serves: 1

	Fat (g)	Protein (g)	Carbohydrate (g) excluding fibre
30 g KetoCal 4:1 Powder (unflavoured)	20.8	4.3	0.9
35 g chicken mince	2.0	9.8	–
5 g egg	0.5	0.6	–
30 g olive oil	30.0	–	–
pinch mixed herbs, dried	–	–	0.1
Total entire recipe	53.2	14.8	1.0

Directions:

Place the minced chicken into a bowl stir

in the egg white, KetoCal 4:1 Powder, season with a good pinch of salt and pepper, dried mixed herbs.

Heat the oil in a frying pan over med/low heat.

Place teaspoons of the chicken mixture into the hot oil with the back of the spoon slightly press down to form a nugget shape or use all the mixture with wet hands and mould into a burger shape and place in the pan (the burger will take longer to cook than the nuggets).

Fry for a few minutes on both sides until fully cooked.

Serve hot, or allow to cool freeze until needed reheat in the oven or air fryer.

IMPORTANT NOTICE: KetoCal is a food for special medical purposes for ketogenic dietary therapy management of epilepsy and Glut1 deficiency syndrome and must be used under medical supervision. KetoCal intake is to be determined by a medical professional and is dependent on the age, weight, energy needs of the individual.

PLEASE NOTE: Nutritional analysis is based on recipes from MyKetoPlanner. Please check individual food labels for exact composition.



